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Abstract
The prevalence of metabolic and stress-related disorders has been on the rise for decades and has
reached epidemic proportions globally. The high degree of comorbidity between these pathological states
is likely due, at least in part, to the significant overlap in neural circuitry that governs energy balance and
stress-related physiological and behavioral responses. The future of pharmacotherapies aimed at treating
these and other disorders relies on a more comprehensive understanding of the molecular interaction
between different neuro-transmitter / -peptide systems. Of particular interest is a growing body of
literature that supports an interaction between serotonin (5-HT) and the central glucagon-like peptide-1
(GLP-1) system, both of which are involved in the control of stress and energy balance. The research
presented in this doctoral dissertation investigates the role of 5-HT as an endogenous modulator of the
central GLP-1 system and its effects on feeding behavior and stress-induced neuronal activation. In
Chapter 2, I establish that the anorectic and body weight changes induced by administration of
exogenous hindbrain 5-HT are dependent on central GLP-1 receptor (GLP-1R) signaling. Second, I provide
anatomical evidence of 5-HT2C and 5-HT3 receptor mRNA expression on GLP-1-producing
preproglucagon (PPG) neurons in the medial nucleus tractus solitarius (NTS). Additionally, I show that
hindbrain activation of these 5-HT receptors induces hypophagia in rats and that this effect is achieved
via central GLP-1R signaling. Finally, a role for the 5-HT3 receptor was identified in mediating anorectic
effect induced by the interoceptive stressor, lithium chloride (LiCl). Chapter 3 explores the 5-HT
modulation of the central GLP-1 system in the context of acute stressors and the potential source of 5-HT
driving the 5-HT/GLP-1 hindbrain interaction. 5-HT2C and 5-HT3 receptors were demonstrated to mediate
the activation of NTS PPG neurons that results from exposure to LiCl and novel restraint. These acute
stressors activate 5-HT activity in the Raphe magnus (RMg), a sub-nuclei of the caudal raphe (CR), as
measured by increased c-Fos expression. Lastly, using a viral tracing technique I confirm that RMg
neurons innervate NTS PPG neurons and that a sub-population of these PPG neurons lie in close
proximity to 5-HT axons. Taken together, the results presented in this document expand the current
understanding of both the central 5-HT and the GLP-1 systems. This collective body of work underscores
the complexity of interactions between two different neural substrates and calls attention to the relevance
such interactions play in the modulation behavioral and physiology.
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ABSTRACT
SEROTONERGIC MODULATION OF THE CENTRAL GLP-1 SYSTEM
Rosa Maria Leon Huamancaja
Matthew R. Hayes

The prevalence of metabolic and stress-related disorders has been on the rise for
decades and has reached epidemic proportions globally. The high degree of comorbidity
between these pathological states is likely due, at least in part, to the significant overlap
in neural circuitry that governs energy balance and stress-related physiological and
behavioral responses. The future of pharmacotherapies aimed at treating these and
other disorders relies on a more comprehensive understanding of the molecular
interaction between different neuro-transmitter / -peptide systems. Of particular interest
is a growing body of literature that supports an interaction between serotonin (5-HT) and
the central glucagon-like peptide-1 (GLP-1) system, both of which are involved in the
control of stress and energy balance. The research presented in this doctoral
dissertation investigates the role of 5-HT as an endogenous modulator of the central
GLP-1 system and its effects on feeding behavior and stress-induced neuronal
activation. In Chapter 2, I establish that the anorectic and body weight changes induced
by administration of exogenous hindbrain 5-HT are dependent on central GLP-1 receptor
(GLP-1R) signaling. Second, I provide anatomical evidence of 5-HT2C and 5-HT3
receptor mRNA expression on GLP-1-producing preproglucagon (PPG) neurons in the
medial nucleus tractus solitarius (NTS). Additionally, I show that hindbrain activation of
these 5-HT receptors induces hypophagia in rats and that this effect is achieved via
vii

central GLP-1R signaling. Finally, a role for the 5-HT3 receptor was identified in
mediating anorectic effect induced by the interoceptive stressor, lithium chloride (LiCl).
Chapter 3 explores the 5-HT modulation of the central GLP-1 system in the context of
acute stressors and the potential source of 5-HT driving the 5-HT/GLP-1 hindbrain
interaction. 5-HT2C and 5-HT3 receptors were demonstrated to mediate the activation of
NTS PPG neurons that results from exposure to LiCl and novel restraint. These acute
stressors activate 5-HT activity in the Raphe magnus (RMg), a sub-nuclei of the caudal
raphe (CR), as measured by increased c-Fos expression. Lastly, using a viral tracing
technique I confirm that RMg neurons innervate NTS PPG neurons and that a subpopulation of these PPG neurons lie in close proximity to 5-HT axons. Taken together,
the results presented in this document expand the current understanding of both the
central 5-HT and the GLP-1 systems. This collective body of work underscores the
complexity of interactions between two different neural substrates and calls attention to
the relevance such interactions play in the modulation behavioral and physiology.
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CHAPTER 1: INTRODUCTION
The Central Glucagon-Like Peptide -1 (GLP-1) System
Glucagon-like peptide-1 (GLP-1) is a hormone that is produced predominantly by L cells
of the small intestine and neurons found within the nucleus tractus solitarius (NTS) of the
caudal brainstem (Baggio and Drucker, 2007; Grill and Hayes, 2012; Holst, 2007; Müller
et al, 2019). GLP-1 is synthesized from the proglucagon protein, which is encoded by
the GCG gene. Proglucagon undergoes tissue/cell-specific forms of post-translational
processing that leads to the formation of GLP-1 in the gut and brain (Han et al, 1986;
Holst, 2007; Larsen et al, 1997a; Müller et al, 2019). GLP-1 was first identified as a
glucoregulatory hormone for its ability to stimulate insulin secretion (Drucker et al, 1987).
A few years later, two separate studies reported that central administration of GLP-1
caused a robust inhibition of food intake (Tang-Christensen et al, 1996; Turton et al,
1996). These studies combined, established GLP-1’s classical role as an incretin and
satiation hormone.

Within the brain, GLP-1 is produced by preproglucagon (PPG) neurons. The expression
pattern of these neurons is significantly conserved between human and rodents (Larsen
et al, 1997a; Llewellyn-Smith et al, 2013; Zheng et al, 2015). While PPG neurons are
most densely expressed in the NTS, they are also found to a much lesser degree in the
intermediate reticular nucleus (IRT), in the olfactory bulb in rat and mouse, and in the
piriform cortex, and lumbrosacral spinal cord of mouse (Merchenthaler et al, 1999; Trapp
and Cork, 2015). Given that PPG neurons in the olfactory bulb are local interneurons
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(Merchenthaler et al, 1999) and those found in the spinal cord do not send ascending
axons to the brain (Llewellyn-Smith et al, 2013), the distribution of PPG axons within the
brain originate almost exclusively from PPG neurons located within the NTS and IRT
(Trapp et al, 2015). PPG projections innervate many midbrain and forebrain regions
including those involved in feeding and stress regulation, as well as the amygdala, the
limbic system, and nuclei involved in autonomic control (Jin et al, 1988; Larsen et al,
1997a; Llewellyn-Smith et al, 2013).

GLP-1 mediates its downstream actions by binding to and activating the GLP-1 receptor
(GLP-1R), of which only a single subtype has been identified (Müller et al, 2019). This
receptor is a G-protein coupled receptor (GPCR) belonging to the class B family
(secretin receptor family). While the GLP-1R couples to different G proteins, including
Gs, Gq, and Gi subunits, the most common pairing is to the Gs subunits which
stimulates intra-cellular second messenger signaling (Fletcher et al, 2016; Hallbrink et al,
2001; Montrose-Rafizadeh et al, 1999). Once activated, GLP-1Rs increase intracellular
calcium levels and the activity of downstream signaling molecules such as adenylate
cyclase, phospholipase C (PLC), protein kinase A (PKA), protein kinase C (PKC),
phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) (Hayes
et al, 2011; Holst, 2007; Rupprecht et al, 2013b). In the brain, GLP-1R are expressed
widely pre- and post-synaptically in the telencephalon, diencephalon, mesencephalon,
and myelencephalon (medulla) (Hayes et al, 2011; Holst, 2007; Jensen et al, 2017;
Merchenthaler et al, 1999).
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GLP-1 and feeding
The role of GLP-1 in mediating feeding behavior was first described in 1996 by two
separate groups. In these initial studies, central administration (intracerebroventricular;
ICV) of GLP-1 was reported to cause an acute, yet robust, reduction of food intake in
rats (Tang-Christensen et al, 1996; Turton et al, 1996). Since then, this anorectic effect
has been recapitulated in other species including mice, birds, pigs, non-human primates,
and humans (Barrera et al, 2009; Gutzwiller et al, 1999; Raun et al, 2007; Scott and
Moran, 2007; Shousha et al, 2007; Verdich et al, 2001). The effect of GLP-1 on feeding
behavior is dose-dependent, can be blocked by pre-treatment with the GLP-1R
antagonist exendin (9-39) (Ex-9), and is absent in GLP-1R knockout mice (Baggio et al,
2004; Barrera et al, 2011a; Larsen et al, 1997b; Turton et al, 1996).

Studies over the past two decades have revealed a clear correlative relationship
between the ingestion of a meal and increased levels of endogenous GLP-1. This mealinduced GLP-1 secretion is present in rodents and humans and is influenced by meal
size (Vilsbøll et al, 2003), composition of the meal (i.e. macronutrient makeup)
(Gunnarsson et al, 2006; Hall et al, 2003; Herrmann et al, 1995; Hirasawa et al, 2005;
Kuhre et al, 2014; Rocca et al, 2001), and gastric distension (Hayes et al, 2009; Vrang et
al, 2003). Native GLP-1 has a half-life of ~2 minutes in both humans and rodents, this is
the result of degradation by the enzyme dipeptidyl peptidase-IV (DPP-IV) and renal
elimination (Deacon et al, 1995; Kieffer et al, 1995; Meier et al, 2004). In humans, the
difference in plasma levels of GLP-1 differ by factor of 4-8 between the fasted and fed
state (Kuhre et al, 2015; Orskov et al, 1996). Increased levels of GLP-1 lead to
3

increased insulin secretion, reduced gastric emptying, reduced food intake, and,
ultimately, reduced body weight (Drucker et al, 1987; Hayes et al, 2010; Imeryüz et al,
1997; Lovshin and Drucker, 2009). The ability of GLP-1 to regulate blood glucose levels,
food intake, and body weight has led to the FDA approval of GLP-1R agonists for the
treatment of type II diabetes mellitus (Lovshin et al, 2009) and obesity (Shukla et al,
2015).

While peripheral GLP-1 is sufficient to regulate the incretin control of glucose
metabolism (Lamont et al, 2012), the anorectic and weight loss effect of GLP-1 is heavily
dependent on its actions within the brain. Support for this comes from studies showing
that the anorectic effect induced by systemic administration of the GLP-1 analogs (i.e
exendin-4 and liraglutide) is attenuated by pharmacological or genetic suppression of
central GLP-1Rs (Kanoski et al, 2011; Sisley et al, 2014). Meanwhile, the weight loss
effect induced by systemic liraglutide is blocked by infusion of the GLP-1R antagonist
(Ex-9) into the arcuate nucleus (ARC) of the hypothalamus (Secher et al, 2014). Using
decerebrate rats, Hayes et al highlighted the relevance of caudal brainstem in mediating
the anorectic effect of the GLP-1R agonist, Ex-4. In this study, hindbrain administration
of Ex-4 reduced food intake in both decerebrate as well as control animals indicating that
hypothalamus and other forebrain regions are not required for its anorectic effect (Hayes
et al, 2008).
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The effect on feeding behavior governed by the central GLP-1 system is complex and
involves the activation of GLP-1Rs in feeding relevant-nuclei—including the dorsal vagal
complex (DVC), the arcuate nucleus (ARC) of the hypothalamus, and the parabrachial
nucleus (PBN)—as well as in nuclei involved in other biological functions—such as the
paraventricular nucleus of the hypothalamus (PVN), the ventromedial hypothalamic
nucleus (VMH), the dorsomedial hypothalamic nucleus (DMH), the ventral tegmental
area (VTA), the nucleus accumbens (NAc), the hippocampus, the laterdal dorsal
tegmental area (LDTg), and the lateral septum [for review see (Kanoski et al, 2016)].
The phosphorylation of the p44/42 MAPK (ERK1/2) signaling pathway and the
suppression of AMPK and Akt activity mediated mediate GLP-1’s anorectic effect (Hayes
et al, 2011; Hurtado-Carneiro et al, 2012; Kanoski et al, 2016). However, the exact
mechanism through which these molecular changes result in reduced feeding is still not
fully understood.

GLP-1 and stress
Stress is defined as a real or perceived disruption of homeostasis or an anticipated
threat to the organisms’ well-being (Ulrich-Lai and Herman, 2009). The physiological
response to stress is governed by two systems: the sympatho-adrenomedullary system
(governed by the autonomic nervous system; ANS) and the hypothalamic-pituitary
adrenocortical (HPA) axis. The first response to stress exposure is the engagement of
the ANS, this response is fast and short-lived and results in increased heart rate,
increased blood pressure, peripheral vasoconstriction, and energy mobilization (the
classic ‘fight or flight’ response). Meanwhile, the activation of the HPA axis is two-step
5

hormonal process that is relatively slower, however, it produces a more amplified effect
by increasing levels of glucocorticoids. In the first step, exposure to stress activates
neurons within the paraventricular nucleus of the hypothalamus (PVN) leading to the
release of corticotropin-releasing hormone (CRH) into the median eminence which
promotes the secretion of adrenocorticotropic hormone (ACTH) from the anterior
pituitary. In the second step, released ACHT enters the circulatory system, travels down
to the adrenal cortex, and initiates the synthesis and release of glucocorticoid hormones
(e.g. corticosterone in rats and cortisol in humans) [for review see (Carrasco and Van de
Kar, 2003; Ulrich-Lai et al, 2009)]. Circulating glucocorticoids promote the mobilization of
energy storage and further engage the sympathetic branch of the ANS, this way the
“fast” and “slow” mechanisms that drive our biological response to stress complement
each other.

The central GLP-1 system is involved in the physiological and behavioral response to
acute and chronic stress [for review see (Ghosal et al, 2013; Herman, 2018; Holt and
Trapp, 2016; Maniscalco and Rinaman, 2017)]. This ability hinges on NTS PPG neurons
playing two roles: 1) sensors of homeostatic disruption and 2) activators of stress
centers (e.g. HPA and ANS). The ability of the NTS to sense changes in homeostasis is,
in large part, a result of its location within the neuroaxis (Grill et al, 2012; Maniscalco et
al, 2012). Located within the caudal hindbrain, the NTS is able to receive homeostatic
signals from the periphery via glutamatergic signaling from the vagus nerve (which
innervates the pharynx, larynx, heart, tracheobronchial tree and lungs, esophagus,
stomach, liver, pancreas, small intestine and proximal colon) and its proximity to the
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area postrema (AP; a circumventricular organ that is highly vascularized and lacks a
blood–brain barrier making it an ideal point of communication between the circulatory
system and the brain parenchyma) makes it sensitive to additional blood-borne signals
(Grill et al, 2012).

The ability of the central GLP-1 system to activate the HPA and the ANS is enabled by
the broad range of its projections and widespread expression of GLP-1Rs within the
brain. Anatomical studies throughout the years using various tracing and imaging
techniques have shown that NTS PPG neurons project to many stress-relevant nuclei
within the hypothalamus (PVN, dorsomedial nucleus, and supraoptic nucleus), forebrain
(bed nucleus of the stria terminalis and central nucleus of the amygdala), brainstem
(reticular formation, dorsal motor nucleus of the vagus, rostral ventrolateral medulla,
raphe nuclei), and spinal cord (sympathetic preganglionic neurons in intermediolateral
column and central autonomic area) (Jin et al, 1988; Larsen et al, 1997a; LlewellynSmith et al, 2013; Llewellyn-Smith et al, 2015; Llewellyn-Smith et al, 2011; Tauchi et al,
2008b; Vrang et al, 2007; Vrang and Larsen, 2010). These two characteristics—location
and extensive branching—enable NTS PPG neurons to receive afferent signals from the
body and relay them via ascending projections to the forebrain (activating HPA axis) and
descending projections to the spinal cord (increasing sympathetic outflow).

The idea that the central GLP-1 system is an important component of stress
neurocircuits is further supported by physiological and neuroendocrine evidence.
7

Electron microscopy data confirms that PPG neurons make synaptic connections with
CRH-containing neurons in the PVN (Sarkar et al, 2003) and these PVN CRH-releasing
neurons co-localize with GLP-1Rs (Ghosal et al, 2017). GLP-1’s ability to activate CRH
neurons has been shown using markers of neuronal activity (i.e. c-Fos expression)
(Larsen et al, 1997b) and electrophysiological in-vitro recordings (Cork et al, 2015).
Further, Peripheral and central administration of either GLP-1 or GLP-1R agonists
increases levels of stress hormones (i.e. ACHT and corticosterone) (Gil-Lozano et al,
2010; Kinzig et al, 2003; Larsen et al, 1997b; Malendowicz et al, 2003) and increases
sympathetic output (raised heart rate and blood pressure) (Yamamoto et al, 2002).

The effect of GLP-1 on stress-related behavior has been studied by a few different
groups. The first set of studies focused on stress-induced hypophagia, showing that the
central administration of Ex-9 attenuates the anorectic effect caused by interoceptive
stressors such as lithium chloride (LiCl) (Rinaman, 1999a), lipopolysaccharide protein
(LPS) (Grill et al, 2004), and cisplatin (De Jonghe et al, 2016). More recent studies have
also linked the central GLP-1 system to hypophagia induced by psychological
stressors—such as physical restraint. Novel restraint (30 minutes) activates NTS PPG
neurons in both rats (Maniscalco et al, 2015) and mice (Terrill et al, 2019). Further,
pharmacological or chemogenetic inhibition of central GLP-1 signaling blocks the
anorectic effect induced by novel restraint (Holt et al, 2019; Terrill et al, 2018).

8

GLP-1 has also been studied in the context of anxiety-like behaviors. An acute central
infusion of GLP-1 or EX-4 increases anxiety-like behavior in the elevated plus maze
(EPM), the open field test, and the light/dark box in rats (Anderberg et al, 2017; Kinzig et
al, 2003; López-Ferreras et al, 2020), whereas inhibition of central GLP-1Rs inhibits
HPA axis response to both psychogenic (EPM and restraint) and interoceptive stressors
(LiCl) and cause a reduction in basal anxiety-like behavior (Ghosal et al, 2017; Kinzig et
al, 2003). Further, parenchymal-specific infusions revealed that the anxiogenic and
endocrine response associated with GLP-1 are region-specific. An infusion of GLP-1 into
the PVN increases corticosterone release but has no anxiogenic effect, while GLP-1
administered into the CeA produces anxiogenic effects but does not cause any changes
in plasma corticosterone levels (Kinzig et al, 2003). This study indicates that NTS PPG
are involved generating physiological and behavioral responses to multiple stress
modalities and that stress-response effects are nuclei-specific.

To summarize, NTS PPG neurons are directly linked to stress centers, they drive HPA
and ANS activity, they activate glucocorticoids release, and they play a role in mediating
stress-related behaviors. The extent to which GLP-1-based therapies can be used
regulate stress-related behaviors is currently under investigation.

Endogenous activators of the central GLP-1 system
Identifying the downstream target nuclei engaged by the NTS PPG neurons has been
the focus of most studies aiming to understand the GLP-1 system. However, not nearly
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much is known about what endogenously activates NTS PPG neurons (aside from
feeding) or how the central GLP-1 system interacts with other hormonal/neurotransmitter
systems. A more comprehensive understanding of the central GLP-1 system is needed
to elucidate how it achieves its broad range of biological functions. Exploring its
interaction with other systems can help develop more efficacious therapeutics for
metabolic and potentially stress-related pathologies.

The central serotonergic 5-HT system
Serotonin (5-hydroxytryptamine; 5-HT) is a classical neurotransmitter derived from the
amino acid tryptophan. Within the body, there are two main sites of 5-HT synthesis, the
brain and the gut. Serotonin synthesized within the brain accounts for <5% of the total
serotonin production in the body, the remaining 95% is synthesized in the periphery
(Berger et al, 2009; El-Merahbi et al, 2015). Peripheral 5-HT is produced mainly by
enterochromaffin cells of the gut, though it is also produced by beta cells, adipocytes,
and osteoclasts (Chabbi-Achengli et al, 2012; Paulmann et al, 2009; Stunes et al, 2011).
Gut-derived 5-HT can act locally within the GI tract or it can be taken up by platelets and
transported via the circulatory system (El-Merahbi et al, 2015). Serotonin cannot cross
the blood–brain barrier (BBB), therefore, its production in gut and brain are isolated from
each other. In serotonin producing cells within the brain, tryptophan is hydroxylated by
the rate limiting enzyme tryptophan hydroxylase 2 (TPH2) and then decarboxylated by
aromatic L-amino acid decarboxylase (AADC) (Keszthelyi et al, 2009). Within the CNS,
5-HT serves as a neurotransmitter and regulates multiple biological functions including
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mood, stress, appetite, glucose homeostasis, and learning (Heisler et al, 2007; Lam et
al, 2010; Lesch et al, 2012; Marston et al, 2011).

The raphe is comprised of multiple sub-nuclei that are categorized into two groups
based on the orientation of their projections. The rostral raphe projects mostly to the
forebrain and contains approximately 85% of all central 5-HT neurons, while the caudal
raphe (CR) projects mainly to the brainstem and spinal cord and accounts for the
remaining 15% of centrally-derived 5-HT neurons (Fig. 1.1) . The rostral raphe is
composed of the caudal linear nucleus, the dorsal raphe, the median raphe, and 5-HT
neurons in the pontomesencephalic reticular formation. While the caudal raphe includes
the raphe pallidus (RPa), raphe obscurus (ROb), and raphe magnus (RMg) (Hornung,
2012; Hornung, 2003; Törk, 1990). From the raphe, 5-HT neurons project to most
regions of the brain including cortical, limbic, midbrain, and hindbrain regions. This high
degree of brain connectivity in combination with a large and complex receptor family
enables the 5-HT system to mediate its diverse functions. There are seven 5-HT
receptor (5-HTRs) families, 5-HT 1-7, which make up fourteen structurally and
pharmacologically distinct 5-HTR subtypes (Fig. 1.2). Most brain regions express
multiple 5-HTR subtypes and even individual neurons can co-express more than one 5HTR subtype (Barnes and Sharp, 1999).
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The 5-HT2C receptor (5-HT2CR)
The 5-HT2CR is a GPCR that couples to a Gq subunit, leading the accumulation of
diacylglycerol (DAG) and inositol triphosphate (IP3) and ultimately resulting in excitatory
neurotransmission. This receptor is expressed post-synaptically and is only found within
the CNS (Barnes et al, 1999; Masson et al, 2012). 5-HT2CR is expressed in many
regions of the brain including the choroid plexus, hippocampus, cerebral cortex,
substantia nigra, and NTS (Abramowski et al, 1995). Among the physiological and
behavioral functions associated with this receptor are hypophagia, anxiety-like behavior,
motivated behavior/impulsivity, locomotion, and thermal regulation [for review see
(Giorgetti and Tecott, 2004; Koek et al, 1992)]. D’Agostino et al. linked the anorectic
effect of 5-HT2CR to its expression within the NTS. In this study selective activation of 5HT2CR in the NTS decreased food intake and its expression within the NTS was
sufficient to mediate the acute anorectic effect induced by 5-HT2CR agonists Lorcaserin
and WAY161,503 (D'Agostino et al, 2018b).

The 5-HT3 receptor (5-HT3R)
The 5-HT3R is the only 5-HTR family whose actions are not mediated by a G protein.
Instead, the -5HT3R is a ligand gated ion channel composed of five symmetrically
arranged subunits that surround a central ion-conducting pore. These subunits can be
identical to produce a homopentameric receptor or different to produce a
heteropentameric

receptor,

these

configurations

differ

in

their

electrical

and

pharmacological properties. Both homopentameric and heteropentameric receptors
mediate a depolarizing inward current that is mainly achieved via transference of sodium
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and potassium ions. A distinguishing difference is that while both receptor types are
permeable to sodium and potassium, the homopentameric receptor (5-HT3A) is also
permeable to calcium ions, while the heteropentameric receptors are not (Thompson
and Lummis, 2006b).

The 5-HT3 receptor is expressed pre- and post-synaptic and can be found in the CNS as
well as the peripheral nervous system (PNS) (Lummis, 2012; Tecott et al, 1993;
Thompson et al, 2006b). Within the brain, 5-HT3Rs are most densely expressed in the
dorsal vagal complex—which is composed of the NTS, AP, and dorsal motor nucleus of
the vagus—highlighting the role this receptor plays in the coordination of the vomiting
reflex (Barnes et al, 1999; Doucet et al, 2000; Thompson et al, 2006b). In addition to
emesis, central 5-HT3Rs have also been linked to anxiety, cognition, and feeding
(Fakhfouri et al, 2019; Hayes and Covasa, 2005; Hayes and Covasa, 2006; Li et al,
2015).

Interaction between the 5-HT and the GLP-1 systems
There is a significant overlap in the expression pattern and biological function of the 5HT and GLP-1 system (Fig 1.3). The first study to showcase the presence of an
interaction between the 5-HT and the GLP-1 systems was published in 2002 (Owji et al,
2002). In this study, central (3V) administration of Ex-4 reduced 5-HT content in the
hypothalamus of rats, while pre-treatment with Ex-9 blocked this effect (Owji et al, 2002).
Since this initial report, many other studies have surfaced providing additional support
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for the presence of this interaction and highlighting its complexity. The literature to date
indicates that the 5-HT and GLP-1 systems interact bidirectionally (5-HT modulating
GLP-1 in some instances, while GLP-1 mediates 5-HT at others) at a cellular and
molecular level within the CNS (Anderberg et al, 2017; Brunetti et al, 2008; Holt et al,
2017; Owji et al, 2002), as well as in periphery (i.e. plasma, colon, and ilium) (Asarian,
2009; Cui et al, 2020b; Lund et al, 2018; Lund et al, 2020; Nonogaki and Kaji, 2015a, b;
Okumura et al, 2020; Ripken et al, 2016; Yang et al, 2014). The interaction between
these two systems has been observed in multiple species —including mice, rats, pigs,
and humans (Anderberg et al, 2017; Aoki et al, 2013; Holt et al, 2017; Martins et al,
2017; Ripken et al, 2016)—and involves different 5-HTRs (Anderberg et al, 2017; Aoki et
al, 2013; Asarian, 2009; Nonogaki et al, 2015b; Nonogaki and Kaji, 2018).

While the presence of the interaction between 5-HT and GLP-1 is well-accepted, the
physiological and behavioral consequences that result from this interaction or whether
these would differ based on site of action is just beginning to be uncovered. A few recent
studies suggest that some of the GLP-1-mediated behaviors (i.e. feeding and
antinociceptive effects) are influenced by its interaction with the serotonergic system. For
example, two different studies showed that the acute anorectic effect of a systemic
administration of GLP-1 was absent in 5-HT2CR null mice (Asarian, 2009; Nonogaki et
al, 2011). Meanwhile, a different study showed that the antinociceptive properties of
GLP-1 on the hot plate test were significantly decreased upon pre-treatment with a 5HT3R antagonist (Aykan et al, 2019). These studies indicate that 1) the interaction
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between these systems is functional and behaviorally relevant and 2) that GLP-1 is
dependent on 5-HTR signaling for some of its behavioral functions.

The ability of 5-HT to act as a modulator of the GLP-1 system has been reported by
different groups. Within the periphery, Ripken et al. showed that 5-HT stimulates GLP-1
release from ileal segments and enteroendocrine cells in vitro (Ripken et al, 2016).
Around the same, time, Nonogaki et al. showed that stimulation of 5-HT1B and 5-HT4
receptors, via systemic administration of pharmacological agonists, increases plasma
levels of GLP-1 (Nonogaki et al, 2015a, b). Of relevance to this dissertation is a 2017
study that assessed the interaction of 5-HT and GLP-1 within the CNS, specifically in the
hindbrain. In this study, Holt et al. showed that a large percent of NTS PPG neurons (5080%) are innervated by serotonergic projections. Additionally, using an in vitro
preparation this group showed that treatment with 5-HT leads to increased calcium
spikes in NTS PPG neurons (Holt et al, 2017). This publication was of particular interest
because it was the first and only study that had assessed the relationship between 5-HT
and GLP-1 within the NTS at the time the work presented in this dissertation began. This
degree of specificity was critical because it showed the direct impact 5-HT has on NTS
PPG neurons, which are the main source of brain-derived GLP-1.

Overview of Dissertation
The existing relationship between the 5-HT system and the GLP-1 system is present in
the brain and periphery and is highly complex—bidirectional, site-specific, involves
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multiple 5-HTR subtypes, and impacts behavioral output. Thus far, the available
literature indicates that the GLP-1 system engages the 5-HT system in some instances,
while the 5-HT system activates the GLP-1 system in others. To date, a single study has
looked at the direct interaction between 5-HT and GLP-1 within the NTS. This study
suggested that within the NTS, 5-HT acts as an activator of the central GLP-1 system
(i.e. PPG neurons) (Holt et al, 2017).

Acquiring increased insight into the interaction between 5-HT and GLP-1 is pivotal to the
development of pharmacotherapies that are more efficacious and have less undesired
side effects. The work presented in this dissertation has three main objectives. First, to
obtain a better understating the modulatory effect 5-HT has on PPG neurons and
exploring the behavioral consequences of that interaction as it pertains to feeding
behavior and stress-mediated neuronal activity. Second, investigating the role the 5HT2C and 5-HT3 receptors play in mediating the serotonergic modulation of NTS PPG
neurons. These receptors became a major focus because of their role in feeding
behavior and because their activity has been linked to the interaction between 5-HT and
the GLP-1. The third and final objective of this dissertation is to identify the potential
source of 5-HT input responsible for engaging the central GLP-1 system.
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Figures

Figure 1.1. Structural organization of the raphe nuclei. The dorsal raphe (in orange)
projects mostly to the forebrain and constitutes around 85% of centrally-derived 5-HT
neurons. The rostral raphe projects mostly to the brainstem and spinal cord, it accounts
for the other 15% of central 5-HT neurons. DR = Dorsal Raphe; MnR = Median Raphe;
MgR = Raphe Magnus; PaR = Raphe Pallidus; ObR = Raphe Obscurus.
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Figure 1.2. The serotonergic receptor family. The 5-HT receptor system is composed
of 7 different families (5-HT1-7) comprising a total of 14 different functional receptor
subtypes.
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Figure 1.3. Overlap in expression and biological function between the 5-HT and
GLP-1 system.
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Abstract

The overlap in neurobiological circuitry mediating the physiological and behavioral
response to satiation and noxious/stressful stimuli are not well understood. The
interaction between serotonin (5-HT) and glucagon-like peptide-1 (GLP-1) could play a
role as upstream effectors involved in mediating associations between anorectic and
noxious/stressful stimuli. We hypothesize that 5-HT acts as an endogenous modulator of
the central GLP-1 system to mediate satiation and malaise in rats. Here, we investigate
whether interactions between central 5-HT and GLP-1 signaling are behaviorally and
physiologically relevant for the control of food intake and pica (i.e., behavioral measure
of malaise). Results show that the anorexia and body weight changes induced by
administration of exogenous hindbrain 5-HT are dependent on central GLP-1 receptor
signaling. Furthermore, anatomical evidence shows mRNA expression of 5-HT2C and 5HT3 receptors on GLP-1-producing preproglucagon (PPG) neurons in the medial
nucleus tractus solitarius by fluorescent in situ hybridization, suggesting that PPG
neurons are likely to express both of these receptors. Behaviorally, the hypophagia
induced by the pharmacological activation of both of these receptors is also dependent
on GLP-1 signaling. Finally, 5-HT3, but not 5-HT2C receptors, are required for the
anorectic effects of the interoceptive stressor LiCl, suggesting the hypophagia induced
by these 5-HT receptors may be driven by different mechanisms. Our findings highlight
5-HT as a novel endogenous modulator of the central GLP-1 system and suggest that
the central interaction between 5-HT and GLP-1 is involved in the control of food intake
in rats.
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Introduction
Many of the nuclei in the brain involved in processing information regarding the control of
food intake are the same nuclei involved in mediating the physiological, behavioral, and
endocrine response to stress. This overlap in neuroendocrine circuitry is thought to be,
in part, responsible for the bidirectional relationship that exists between energy balance
and the physiological responses to interoceptive stress or noxious stimuli (Ulrich-Lai and
Ryan, 2014). The ingestion of food produces physiological responses similar to those
initiated by stress, including increased plasma levels of glucocorticoids(Moberg et al,
1975), adrenocorticotropic hormone (Slag et al, 1981) and epinephrine (Steffens et al,
1986). While, the role of classical stress centers, such as the hypothalamic-pituitaryadrenal axis (HPA), are well-established much less is known about common upstream
neurobiological substrates involved in partitioning the downstream effector circuitry and
behavioral outputs of the physiological responses to noxious / stressful stimuli from
those of normal ingestive behavior. A growing body of literature supporting an interaction
between serotonin (5-HT) and the glucagon-like peptide-1 (GLP-1) (Anderberg et al,
2016; Brunetti et al, 2008; Holt et al, 2017; Nonogaki et al, 2015b; Owji et al, 2002;
Ripken et al, 2016; Yang et al, 2014) system has implicated these systems in the
regulation of physiological responses to stress / noxious stimuli, as well as the control of
food intake (Bagdy et al, 1989; Barrera et al, 2011a; Barrera et al, 2011b; Grill et al,
2004; Heisler et al, 2007; Holt et al, 2016; Kinzig et al, 2003; Lam and Heisler, 2007;
Owens and Nemeroff, 1994; Pollock and Rowland, 1981; Rinaman, 1999a, b; Turton et
al, 1996).
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GLP-1 is an anorectic hormone involved in the regulation of food intake (Barrera et al,
2011b), glycemic control (Cabou et al, 2008), stress (Grill et al, 2004; Holt et al, 2016;
Rinaman, 1999a, b), and nausea (De Jonghe et al, 2016; Kanoski et al, 2012). Centrally,
GLP-1 is produced by preproglucagon (PPG) neurons located predominately in the
nucleus tractus solitarius (NTS), which sends projections to GLP-1-receptor (GLP-1R)expressing nuclei throughout the brain (Merchenthaler et al, 1999). PPG neurons are
activated by multiple satiation signals (e.g. gastric distension(Hayes et al, 2009) and
cholecystokinin (Trapp et al, 2015)), as well as various interoceptive stressors [e.g.
lipopolysaccharides (Grill et al, 2004), lithium chloride (Rinaman, 1999a, b), and cisplatin
(Kanoski et al, 2012)]. Despite the growing appreciation of the downstream nuclei
targeted by the central GLP-1-producing PPG neurons, much less is known about the
upstream signaling mechanisms that facilitate endogenous PPG activation in response
to these stimuli.

Similar to the central GLP-1 system, the central serotonergic system controls for food
intake (Pollock et al, 1981), regulates central stress centers (such as the HPA) (Bagdy et
al, 1989; Heisler et al, 2007), and mediates nausea, malaise and emesis(Cubeddu et al,
1992)me. Additionally, 5-HT is critically important for a number of neurobiological
functions (e.g. mood, reward, appetite, attention) (Berger et al, 2009) and is a common
target for therapeutics, including the most common used type of antidepressants
(selective serotonin reuptake inhibitors; SSRIs) (Booij et al, 2002; Delgado, 2000). While
the enterochromaffin cells of the small intestine produce roughly 90% of the body’s total
5-HT (Gershon and Tack, 2007), a small percent of 5-HT is also produced in the central
nervous system (CNS), mainly in the Raphe nuclei (Donovan and Tecott, 2013). These
23

serotonergic neurons exhibit widespread projections throughout the brain, signaling
through its large and complex receptor system, comprised of 14 different functional
receptor subtypes (Barnes et al, 1999). Although multiple 5-HTRs are expressed within
the NTS (Abramowski et al, 1995; Doucet et al, 2000; Laporte et al, 1992), the 5-HT2C
receptors (5-HT2CR) and 5-HT3 receptors (5-HT3R) are of particular interest given their
excitatory properties (Barnes et al, 1999), role in regulating food intake (D'Agostino et al,
2018a; Mazzola-Pomietto et al, 1995; Redman and Ravussin, 2010) and illness-like
behaviors (Higgins et al, 2013; Thompson and Lummis, 2007), as well as their clinical
relevance; i.e. both the 5-HT2CR agonist, Lorcaserin, and the 5-HT3R antagonist,
Zofran, are FDA-approved to treat obesity and nausea, respectively.

5-HT and GLP-1 interact bidirectionally at a cellular and molecular level in the periphery
[e.g. plasma (Nonogaki et al, 2015b), colon (Yang et al, 2014), and ileum (Ripken et al,
2016)] and in the CNS (Holt et al, 2017; Owji et al, 2002). Holt et al (2017) showed that
in mice, 50-80% of NTS PPG neurons are innervated by serotonergic projections and
that treatment with 5-HT leads to increased calcium spikes in PPG neurons. These
results suggest that, at least within the NTS, the directionality of this interaction favors 5HT acting as a modulator of PPG neuron activity. However, whether this directionality is
maintained in rats and what are the underlying mechanisms and behavioral
consequences of this interaction remain unexplored. Here, we sought to investigate the
role of 5-HT as a regulator of GLP-1-producing PPG neurons in the regulation of energy
balance, specifically as it relates to hypophagia and malaise/nausea in rats. The three
main goals of this study were to: 1) determine whether 5-HT engages the central GLP-1
system to induce hypophagia and kaolin intake, 2) assess the role of the 5-HT2C and 524

HT3 receptors in mediating these effects, and 3) investigate whether the 5-HT/GLP-1
interaction is also involved in mediating the hypophagia induced by the interoceptive
stressor, LiCl.
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Materials and Methods
Animals
Male Sprague Dawley rats (350–365g upon arrival; Charles River) were individually
housed in hanging wire cages maintained at 23°C (12h reversed light/dark cycle) and
given ad libitum chow (Purina LabDiet 5001) and water. All procedures were approved
by Institutional Animal Care and Use Committees at the University of Pennsylvania and
were performed in accordance with National Institute of Health animal experimentation
guidelines.

Drugs and delivery sites
The competitive GLP-1R antagonist, exendin-(9-39) (Ex9; Bachem, 4017799), serotonin
chloride (5-HT; Tocris, 3547), selective 5-HT2CR agonist, lorcaserin (Lor; KeyOrganics,
KS1439), and selective 5-HT3R agonist, SR57227 (SR5; Tocris, 1205), were all
dissolved in artificial cerebrospinal fluid (aCSF; Harvard Apparatus, 59-7316). The
selective 5-HT3R antagonist, ondansetron (OND; Tocris, 2891), and 5-HT2CR
antagonist, RS102221 (RS1; Tocris, 3969) were dissolved in 100% DMSO (Research
Organics, 2166D). LiCl (Sigma, L4408) was dissolved in 0.9% sterile saline for
peripheral injections, intraperitoneal (i.p.) route of administration. Aside from LiCl, all
other drugs were administered centrally in a 1µl volume into either the 4th ventricle (4th
ICV) or lateral ventricle (LV).

Stereotaxic surgery
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Animals were anesthetized with an intramuscular injection of an anesthetic cocktail
(KAX) composed of ketamine (Butler Schein; 90mg/kg), acepromazine (Midwest
Veterinary Supply; 0.64mg/kg), and xylazine (Midwest Veterinary Supply; 2.7mg/kg) and
placed in a stereotaxic apparatus afer reaching proper anesthesia depth. Single guide
cannulae (26 gauge; Plastics One, Roanoke, VA) targeting the 4th ICV and/or LV were
implanted (4th ICV coordinates: midline, 2.5mm anterior to the occipital suture, the
indwelling cannula aimed 5.2mm ventral to skull; LV coordinates: 1.6mm to the right of
the midline, 0.9 mm posterior to bregma, internal cannula aimed 2.8mm ventral to skull;
Paxinos and Watson, 2005) and affixed to the skull with bone screws and dental cement.
Analgesia (meloxicam; Midwest Veterinary Supply; 2mg/kg) was administered
subcutaneously for the first 3 days following surgery. Rats were given one week to
recover from surgery before starting behavioral testing. For microinjections, 33 gauge
microinjector (Plastics One) that extended an additional 2.0mm beyond the length of the
cannula were used. Fourth ventricle cannula placements were verified by assessing the
hyperglycemic

response

to

5-thio-D-

glucose

(210µg/2µl),

as

described

previously(Hayes et al, 2008). The LV placement was verified with angiotensin II
(10ng/1µl) drinking test(Richard et al, 2015). Verifications were conducted prior to
starting behavioral testing, only animals that passed their relative verifications were
tested.

Fluorescent in situ hybridization (FISH)
Tissue harvest. Rats (n=4) were anesthetized with KAX and decapitated. Brains were
quickly removed and subsequently frozen in cold hexane (Honeywell) and stored at
-80°C. Coronal sections (20µm) containing the DVC/NTS at the level of the obex
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(approx. 14.15 to 14.64mm posterior to bregma) were obtained using a cryomicrotome
(Leica Microsystem) and immediately mounted onto Superfrost Plus slides (Fisher).

mRNA expression of PPG, 5-HT2CR, and 5-HT3R at the level of the medial NTS.
Fluorescent in situ hybridization was carried out using RNAscope Multiplex Fluorescent
Reagent Kit V2 (Cat. 323100; Advanced Cell Diagnostics (ACDBio), Hayward, CA) per
the manufacturer’s protocol. Briefly, slide mounted sections were rinsed in 4%
paraformaldehyde for 15 min at room temperature (RT). Following two quick rinses in
0.1M PBS the sections were dehydrated in ascending ethanol solutions (5 min washes
in 50, 70, 100, 100% ethanol) followed by an overnight incubation in 100% ethanol at

-

20°C. Next, slides were air-dried and a hydrophobic barrier was made around all of the
sections on the slide using an hydrophobic pen (Vector Labs). The sections were treated
with H2O2 for 10 min at RT (followed by 3 X 1min in PBS) and Protease IV for 30 min at
RT (followed by 2 X 1 min rinses in PBS).

Pretreated tissue sections were processed immediately using probes designed by ACD
to detect PPG mRNA (Rn-Gcgs-C3; 315471-C3), 5-HT2C mRNA (Rn-Htr2c-C2; 469321C2), and 5-HT3A mRNA (Rn-Htr3a; 480041). Sections were incubated in a cocktail
containing all three probes (concentrations indicated by manufacturer) for 2hr at 40oC in
a HybEZTM oven (ACDBio). Slides were rinsed twice in RNAscope wash buffer followed
by a series of amplification steps at 40oC separated by two brief washes in RNAScope
wash buffer (ACDBio): 30 min FL v2 AMP1 (ACDBio; 320852), 15 min FL v2 AMP2
(ACDBio; 320853), 30 min FL v2 AMP3 (ACDBio; 320854), and then 15 min FL v2
AMP4A (ACDBio 320855; C1 Alexa 488nm; C2, Atto 550nm; C3 Atto 647nm). After the
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final wash buffer, slides were coverslipped using Fluorogel mounting medium with DAPI
(Fisher).

Image Acquisition, processing, and quantification. Sections were visualized with a Leica
SP5 X confocal microscope using the 20x and 40x oil-immersion objectives and the 405,
488, 555, and 647 laser lines. Image z-stacks were collected with the 20x and 40x oilimmersion objective with a step size of 2µm; at 40x a 2–4x optical zoom was used to
image individual neurons. All images were collected sequentially to avoid contamination
of signals from other fluorophores. The collected z-stack images were processed to
reduce background and create three-dimensional rotational animations using Imaris
8.1.2 (Bitplane). Every PPG neuron that was identified at the level of the obex (14.15 to
14.64mm posterior to bregma) was quantified in each section that was imaged.
Colocalization of 5-HTRs on PPG neurons was quantified manually on Imaris following
background subtraction. All images were taken within 5 days of completing FISH and all
sections coming from the same animal were imaged on the same day to limit difference
in fluorescence.

Feeding Behavior
In these studies, kaolin intake (i.e., pica) was used as a model of illness-like behaviors
(i.e proxy for nausea/malaise). Pica is the ingestion of a non-nutritive material, such as
clay (or in a lab setting kaolin pellets) in response to toxicosis. Since rodents lack the
vomiting reflex,

kaolin intake has been established as a model of malaise in rats

(Andrews and Horn, 2006). A series of behavioral, pharmacological, and molecular
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techniques were employed to test the hypothesis that activation of 5-HT2CR and 5HT3R modulates central GLP-1 signaling to influence food intake and pica.

General procedures. Rats were handled daily, pre- and post-surgery, and were
habituated to ICV and intraperitoneal (i.p.) injections for five consecutive days before
beginning experimentation. Drug injections were performed immediately prior to the
onset of the dark cycle unless otherwise specified. For experiments measuring ad libitum
food intake, food weights were recorded to the nearest 0.1g, accounting for spillage.
Chow intake was measured at 1, 3, 6, and 24h post-injection and body weight was
measured at 0 and 24h post-injection. To measure pica, rats were habituated to a
second hopper containing kaolin pellets (Research Diets, K50001) for 5-7 days week
prior to the experiment. Following 2-4 days of habituation, 24h baseline chow and kaolin
intake readings were taken for 1-2d before testing begun. During testing, kaolin intake
was recorded at 0 and 24h post-injection, accounting for spillage. Treatments were
assigned using a within-subject counter-balanced design and separated by 48h between
injections, except when noted.

Experimental Procedures

GLP-1R blockade on 5-HT-induced chow intake suppression and increased kaolin
intake. Rats (n=30) received a 4th ICV injection of 5-HT (40µg) or aCSF followed by LV
injection of a subthreshold dose of Ex9 (20µg)(Barrera et al, 2009) or aCSF. Dose of 5HT was chosen based on our previous published and unpublished work examining. 5HT-mediated suppression of intake (Hayes et al, 2005). Chow intake and body weight
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were measured as described in general procedures. Following habituation and baseline
testing (see general procedures for details), the effects of 40µg of 5-HT (4th ICV) on
kaolin intake was measured in a group of rats (n=13). Chow intake, body weight, and
kaolin intake were measured as described in general procedures.

Chow intake, kaolin intake, and body weight induced by pharmacological agonists of
5-HT2CR or 5-HT3R. Rats received 4th ICV injections of either Lor (0, 2, 10, or 20µg;
n=9) or SR5 (0, 5, 10, or 20µg; n=11). Chow intake was measured as described in
general procedures. Experimental procedures for each agonist were run in separate
cohorts of rats. Effect of Lor (n=8) and SR5 (n=21) on 24h body wight and 24h kaolin
intake was measured in a separate group of rats (20µg 4th ICV for both agonists).

Central blockade of GLP-1R signaling on 5-HT2CR- and 5-HT3R-induced chow and
kaolin intake. Rats were treated with Ex9 (20µg; LV) or aCSF following treatment with
either Lor or aCSF (n=20), or SR5 or aCSF (n=19) (20µg 4th ICV for both agonists).
Experimental procedures for each of these agonists were run in separate cohorts of rats.
Chow intake, body weight, and kaolin intake were measured as described in general
procedures.

Validation of RS102221. First, a dose response analysis of RS1 (5-HT2CR antagonist)
was conducted in a group of animals (n=16). In this cohort, chow intake was measured
following 4th ICV treatment with either 0, 10, 20, 40µg of RS1. A separate cohort of rats
(n=10) was pre-treated with 40µg of RS1 (40µg; 4th ICV) followed by Lor (20µg; 4th ICV),
chow intake was measured at 1 and 3h post-injection.
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Hindbrain blockade of specific of 5-HTR subtypes on LiCl-induced chow intake
suppression. Rats were pre-treated with either the RS1 (40µg; n=8) or DMSO, or OND
(25µg; n=14) or DMSO (4th ICV for both agonists), this was followed by a systemic
injection with 0.15M LiCl (20ml/kg; i.p.) or saline. Experimental procedures for each of
these antagonists were run in separate cohorts of rats. Chow intake was measured at 1
and 3h post-injections.

Statistical analyses
All data are represented as mean ± SEM with the α-level set to p = 0.05. For behavioral
studies, the data was binned and analyzed using either a repeated measures two-way
ANOVA followed by a Newman Keuls post-hoc analysis when appropriate or a repeated
measures one-way ANOVA followed by a Dunnet pos- hoc analysis when appropriate.
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Results
Central Blockade of GLP-1Rs Attenuated the Anorectic and Body Weight-Reducing
Effects of Hindbrain 5-HT
The effect of hindbrain administration of 5-HT on chow intake, body weight, and kaolin
intake was measured in a group of rats (n=18) by administering 40µg of 5-HT (4th ICV).
At this dose, 5-HT decreased chow intake at 1, 3, 6, and 24h post-injection, decreased
24h body weight, and increased 24h kaolin intake compared to vehicle-treated controls
(all p<0.01, Fig. 2.1a-c). To determine whether the effects of 5-HT on chow and kaolin
were dependent on central GLP-1 signaling, a separate cohort of rats (n= 30) received a
LV administration of Ex9 (20µg) following 4th ICV treatment with 5-HT (40µg). As
expected, 5-HT significantly suppressed chow intake at 1, 3, 6, and 24h post-injection
and Ex9 alone had no effect (Fig. 2.2a). A significant interaction between 5-HT and Ex9
was detected at each timepoint [1h(F1,29 ≥ 7.8; p<0.01); 3h(F1,29 ≥ 8.4; p<0.01); 6h(F1,29 ≥
10.8; p<0.01); 24h(F1,29 ≥ 12.3; p<0.01)]. Post-hoc analyses revealed that treatment with
Ex9 reversed the anorectic effects of 4th ICV 5-HT at 1, 3, 6, and 24h post-injection
(Newman-Keuls; all p<0.01). Ex9 also reversed the reduction in 24h body weight
induced by 5-HT (F1,29 ≥ 4.2; p<0.05) (Fig. 2.2b). In another group of animals (n=13) in
which 24h kaolin intake was measured, there was a main effect of 5-HT (F1,12 ≥ 11.1;
p<0.01), however, treatment with Ex9 did not attenuate this effect (Fig. 2.2c).

Heterogeneous mRNA expression of serotonergic receptors, 5-HT2R and 5-HT3R, on
rat PPG neurons in the medial NTS
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Fluorescent in situ hybridization was conducted on coronal sections containing medial
NTS (mNTS) at the level of obex (Fig. 2.3a), to determine whether PPG neurons (blue)
express 5-HT2CR (magenta) and 5-HT3R (green) transcripts (n=4; 3-5 sections per
animal were imaged). Co-localization between PPG and 5-HT2CR and 5-HT3R
transcripts (Fig. 2.3b) indicates that rat PPG neurons in the mNTS transcribe message
for both of these serotonergic receptor subtypes. Furthermore, there was a high degree
of heterogeneity observed in the mRNA expression levels of these receptors among
PPG neurons. Some PPG neurons expressed mainly the 5-HT2C, while others
expressed both transcripts to varying degrees (Fig. 2.3c). The heterogeneity observed
seemed to be random, with no detectable patterns of expression in rostral-caudal plane
or medial-lateral. Additionally, there were no differences in expression between
hemispheres. A three-dimensional rotation video of 40X z-stack overlays looking at 5HTRs on PPG neurons corroborated message of these receptors within PPG neuron as
opposed to adjacent neurons (Fig. 2.3e, Video 1). This approach avoids the possibility
of false overlaps that may exist in the two-dimensional image. Quantification revealed
that 90% of PPG neurons expressed 5-HT2CR mRNA, 62% of PPG neurons expressed
5-HT3R mRNA, and 55% of PPG neurons expressed mRNA for both receptors (data
was calculated as average expression per animal) (Fig. 2.3d).

Activation of Hindbrain 5-HT2CR Acutely Suppressed Feeding Without Affecting
Malaise, an Effect that is Dependent on Central GLP-1 Signaling
The 5-HT2CR agonist, lorcaserin (Lor), is well characterized and has been used
extensively in rodents to study its acute anorectic effects following peripheral
administration (Higgins et al, 2013; Thomsen et al, 2008). We performed a dose34

response analysis in order to identify a central (4th ICV) dose that would induce a
comparable anorectic effect. Lor was administered at 0, 2, 10, 20µg (n=9), these doses
chosen were based on the intake-suppressive effects of Lor upon peripheral
administration in rodents (Higgins et al, 2015; Higgins et al, 2016; Thomsen et al, 2008).
A main effect of Lor on chow intake was detected at 1 and 3h [1h (F3,24 ≥ 6.8; p<0.01); 3h
(F3,24 ≥ 4.4; p<0.05)], but not at 6 and 24h. All three doses of decreased chow intake at
1h, while only the 10 and 20µg doses significantly decreased chow intake at 3h (Dunnet;
all p<0.05) (Fig. 2.4a). To assess whether nausea/malaise contributes to the intake
suppression following hindbrain activation of 5-HT2CR, kaolin intake was measured in a
separate group of rats (n=8) receiving 20µg of Lor (4th ICV). At this dose, Lor had no
effect on 24h body weight (Fig. 2.4b) or kaolin intake (Fig. 2.4c).

To determine whether central GLP-1 signaling is necessary for the 5-HT2CR induced
anorectic effect, rats were treated with 20µg Ex9 (LV) following a 4th ICV injection 20µg
of Lor (n=20) (Fig. 2.4d-f). A significant interaction between Lor and Ex9 was detected at
1 and 3h [1h(F1,19 ≥ 5.898; p<0.05); 3h (F1,19 ≥ 10.48; p<0.01)]. Post hoc analyses reveal
that Ex9 reversed the anorectic effects of 4th ICV Lor at 1 and 3h post-injection (Newman
Kleus; all p<0.01) (Fig. 2.4d). Lor and Ex9 alone or in combination had no effect on 24h
body weight (Fig. 2.4e) or 24h kaolin intake (Fig. 2.4f). These findings indicated 5HT2CR activation within the hindbrain suppresses food intake in a GLP-1 dependent
manner, without eliciting nausea/malaise.

Activation of Hindbrain 5-HT3R Suppressed 24h feeding, an Effect that is Dependent on
Central GLP-1 Signaling
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The 5-HT3R agonist, SR57227 (SR5), acutely suppresses food intake in rodents upon
peripheral administration (Li et al, 2015). Again, we performed a dose-response analysis
to identify a central (4th ICV) dose that results in comparable anorectic effects. SR5 was
injected at 0, 5, 10, 20µg (n=11), doses were chosen and adapted based on the
anorectic effects reported by Li et al. (2015) upon peripheral administration in mice(Li et
al, 2015). A main effect of SR5 on chow intake was detected at all timepoints [1h(F3,30 ≥
7.0; p<0.01); 3h (F3,30 ≥ 4.3; p>0.05); 6h (F3,30 ≥ 8.0; p<0.001); 24h (F3,30 ≥ 6.6; p<0.01)].
The 5µg dose significantly suppressed chow intake at 6h, while the 20µg dose
decreased chow intake at all timepoints (Dunnet; all p<0.05) (Fig. 2.5a). To determine
whether malaise/nausea contributes to the intake suppression induced by hindbrain
activation of 5-HT3R, 24h kaolin intake was measured in a separate cohort (n=21).
Treatment with 20µg of SR5 (4th ICV) prevented the 24h body weight gain that was
observed in the vehicle-treated rats and significantly increased kaolin intake (all p<0.01;
Fig. 2.5b-c). These results suggest that activation of hindbrain 5-HT3R suppresses
chow intake and that, unlike the anorectic effect caused by activation of hindbrain 5HT2CR, this suppression involves mechanisms related to malaise.

To assess if central GLP-1 signaling is required for the anorectic effects induced by
hindbrain activation of 5-HT3R, rats were treated with 20µg of Ex9 into the LV following
a 4th ICV injection of SR5 (20µg) (n=19; Fig. 2.5d-f). There was a main effect of SR on
chow intake at all timepoints [1h(F1,18 ≥ 23.97; p<0.001); 3h (F1,18 ≥ 20.26; p<0.001);
6h(F1,18 ≥ 7.522; p<0.05); 24h (F1,18 ≥ 8.617; p<0.001)]. A significant interaction between
SR5 and Ex9 was also detected at all timepoints [1h(F1,18 ≥ 6.197; p<0.05); 3h (F1,18 ≥
9.675; p<0.01); 6h(F1,18 ≥ 15.88; p<0.001); 24h (F1,18 ≥ 27.3; p<0.001)]. Post hoc
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analyses reveal that Ex9 reverses the anorectic effects of 4th ICV SR5 at 6 and 24h
(Newman Kleus; all p<0.01), but not at 1 and 3h post-injection (Fig. 2.5d). SR5 and Ex9
alone or in combination showed no effect on 24h body weight (Fig. 2.5e) or kaolin intake
(Fig. 2.5f).

Hindbrain Blockade of 5-HT3R, but not 5-HT2CR, Reversed LiCl-Induced Chow Intake
Suppression
The anorectic effects of the interoceptive stressor LiCl is mediated, in part, by the central
GLP-1 system (Rinaman, 1999a, b). Given the evidence that hindbrain 5-HT has a
modulatory effect on central GLP-1 signaling and that this effect seems to involve the
activation of 5-HT2CR and 5-HT3R, we investigated whether a pharmacological
blockade of these receptors would be sufficient to attenuate the anorectic effect induced
by LiCl. Based on our data thus far, we hypothesized that activation of 5-HT3R, but not
the 5-HT2CR, on PPG neurons mediate the anorexia induced by LiCl.

We first sought to validate the effectiveness of RS1 as a 5-HT2CR antagonist, as we
could not find a study looking at its effect on food intake. Fourth ventricular
administration of RS1 at 10, 20, or 40µg did not increase chow intake (n=16) (Fig. 2.6a).
However, a pre-treatment with RS1 (40µg) significantly reversed the anorectic effect
induced by 4th ICV Lor at 1h (n=10) (F1,9 ≥ 20.17; p<0.01) (Fig. 2.6b). Next, we tested
whether a sub-threshold dose of RS1 (a dose that would not have an effect on feeding
behavior on its own) could attenuate the anorectic effect induced by 0.15M LiCl
(20ml/kg; a dose known to elicit anorectic effects (Lawrence et al, 2002)). Treatment with
0.15M LiCl (20ml/kg) did no alter 24h body weight, but significantly suppressed food
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intake and increased 24h kaolin intake (all p>0.01, S1a-c) (Fig. 2.7a-c). Rats (n=8)
received 4th ICV RS1 (40µg) followed by a systemic (i.p.) injection of 0.15M LiCl
(20ml/kg). Chow intake was measured at 1, 3, 6, and 24h, but only 1 and 3h of
cumulative chow intake are shown in the figure (this applies to Figure 2.5d-e). A main
effect of LiCl was detected at all timepoints [1h (F1,7 ≥ 27.13; p<0.01); 3h (F1,7 ≥ 92.79;
p<0.001)]. Post hoc analyses reveal revealed RS1-pretreatment had no effect on chow
intake at any timepoint (Fig. 2.7d).

Next, we tested if the blockade of 5HT3R via OND would could attenuate the LiClinduced anorexia. The dose of OND was chosen based on literature indicating that upon
4th administration 25µg has no effect on chow intake (Hayes et al, 2006). Rats (n=14)
received 4th ICV OND (25µg) followed by a systemic (i.p.) injection of 0.15M LiCl
(20ml/kg). In this case, a significant interaction between OND and LiCl was present at 1
and 3h [1h (F1,13 ≥ 10.94; p<0.01); 3h (F1,13 ≥ 7.991; p<0.005)]. Post hoc analyses reveal
that pre-treatment OND attenuated the anorectic effect of LiCl at 1h and reversed it at 3h
post-injection (all p<0.05) (Fig. 2.7e).
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Discussion
The central GLP-1 system is engaged by physiological satiation signals, as well as
noxious stimuli, toxins and stressful stimuli [see (Hayes et al, 2014; Kanoski et al, 2016)
for review]. In an attempt to uncover a novel neural substrate responsible for engaging
the complementary and diverse set of physiological / behavioral outputs from the central
GLP-1 system, we focused our attention on the central serotonergic system due to its
action as a satiation signal (D'Agostino et al, 2018a; Pollock et al, 1981) and mediator of
stress (Bagdy et al, 1989; Heisler et al, 2007) and malaise responses (Cubeddu et al,
1992). Here, we show that the hypophagic effects of hindbrain 5-HT is dependent on
central GLP-1R signaling. This 5-HT-mediated activation of central GLP-1 signaling was
further shown to be mediated by 5-HT2C and 5-HT3 receptors. To this end, FISH
analyses revealed mRNA expression of both 5-HT2C and 5-HT3 receptors within PPG
neurons in the medial NTS. The hypophagia induced by specific agonists of these
receptors in the hindbrain was also shown to be reversed by blockade of CNS GLP-1R
by LV ICV administration of Ex9. Finally, while the hypophagia induced by activation of
hindbrain 5-HT3R was shown to involve a partial engagement of illness-like behaviors
(as shown by increased kaolin intake), activation of 5-HT2CR suppressed food intake via
a GLP-1 dependent mechanism devoid of this behavior. These results suggest that the
hypophagia induced by hindbrain activation of the 5-HT2CR and 5-HT3R is driven by
different behavioral mechanisms (e.g. satiation vs. noxious mediated hypophagia,
respectively). Collectively, these results indicate that the interaction between 5-HT and
GLP-1 within the hindbrain is relevant for the control of food intake, an effect that seems
to involve activity of the 5-HT2C and 5-HT3 receptors.
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The interaction between 5-HT and GLP-1 is bidirectional and site specific (Holt et al,
2017; Owji et al, 2002). Of note, a recent study by Holt et al (2017) showed within the
NTS, 5-HT signaling has a modulatory effect on central GLP-1 signaling in mice. In
trying to understand whether this effect is achieved through a direct modulation, we
looked at mRNA expression of 5-HT2C and 5-HT3 receptor subtypes on PPG neurons.
While many of the 5-HT receptor subtypes, including the 5-HT2C and 5-HT3, are
expressed in the NTS (Abramowski et al, 1995; Laporte et al, 1992), the phenotype of
these cell population(s) remain unclear. Using FISH, observed expression of 5-HT2CR
and 5-HT3R transcripts within rat PPG neurons in the medial NTS. Transcript receptor
expression was heterogenous, with the 5-HT2CR being more commonly expressed than
the 5-HT3R. Intriguingly, these data differ from previous reports that utilized
electrophysiology to positively identify the presence of 5-HT2CR, but not 5-HT3R in PPG
neurons of mice (Holt et al, 2017). While the different methodological approaches could
play a role in the distinction of these findings, species differences within the GLP-1
system are not uncommon. Some of these differences between rat and mouse include
effects on glucose metabolism (Arora et al, 2016; Pérez-Tilve et al, 2010), anatomical
distribution of PPG neurons (Cork et al, 2015; Tang-Christensen et al, 1996), and of
relevance to the current data, a divergence in behavioral responses mediated by the
central GLP-1 system to noxious stimuli (Lachey et al, 2005). Additionally, given that 5HT3R do not always engage calcium signaling when activated but instead depolarize the
cell via Na+ (Stewart et al, 2003) it would be useful to obtain anatomical verification of 5HTR expression on PPG neurons in mice, as well other animal models, especially those
with a vomiting reflex such as the shrew, ferret, dog, or primate.
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Central blockade of GLP-1Rs prevented hindbrain 5-HT-induced hypophagia and
reduction of 24h body weight. These results provide further evidence that within the
hindbrain, 5-HT has a modulatory effect on CNS GLP-1 signaling and sets forth 5-HT as
a novel upstream modulator of central GLP-1 signaling. The inability of Ex9 to block the
kaolin intake observed following hindbrain 5-HT treatment could be the consequence of
an insufficient dose of Ex9 reaching the nuclei involved in the mediation of nausea and
not attribute to a lack of contribution from the GLP-1 system as a whole. Indeed, Ex9
(20µg) was delivered into the LV with the intention of providing a broad total CNS
blockade of GLP-1R signaling within the brain at a dose that would not, on its own,
increase food intake. A caveat to this approach is the rate of diffusion and biodistribution
of Ex9 throughout the brain cannot be controlled with a LV administration. Hence, more
caudal GLP-1R-expressing nuclei, including those driving the vomiting center (e.g. NTS /
area postrema) likely received a much lower dose of Ex9. In the future, we are interested
in targeting specific GLP-1R-expressing nuclei to explore the different mechanisms
involved in mediating 5-HT’s anorectic effects through engagement of the central GLP-1
system.

Hindbrain activation of 5-HT2CR and 5-HT3R independently suppressed chow intake in
a central GLP1-dependent manner. A dose response analysis identified 20µg of the 5HT2CR agonist, Lor, sufficient to induce anorexia 1 and 3h post-injection without
affecting body weight or kaolin intake. These results are in line with previous report
showing a short-lived anorectic effect following 5-HT2CR activation and lack of effect on
body weight following a single administration. In contrast, 20µg of the 5-HT3R agonist,
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SR5, led to a much longer anorectic effect that was significant up to 24h post-injection.
Additionally, hindbrain activation of 5-HT3R prevented body weight gain and stimulated
kaolin intake. These behavioral differences highlight a temporal and potentially
behavioral (anorectic vs. noxious mediated hypophagia) dissociation between the
anorectic effects induced by the activation of these different 5-HTRs. The role of the 5HT2CR as a modulator of satiety is well-established (D'Agostino et al, 2018a; Lam et al,
2008; Xu et al, 2008) and is reflected by its expression on nuclei involved in regulating
energy balance such as the arcuate nucleus of the hypothalamus (Heisler et al, 2002)
and the NTS (D'Agostino et al, 2018a). Meanwhile, CNS expression of the 5-HT3R is
widespread (Thompson and Lummis, 2006a). While activation of both, 5-HT2CR and 5HT3R, reduce food intake, it’s likely that this anorectic effect is driven by a set of partially
overlapping mechanisms involving satiety and malaise, respectively. This is supported
by our findings that the anorectic effect of the interoceptive stressor, LiCl, is reversed by
blockade of hindbrain 5-HT3R, but not 5-HT2CR. However, we stress that a wealth of
future research is needed to further disentangle the contribution of these two 5-HT
receptor subtypes in engaging PPG neurons in response to both physiological and
pathophysiological stimuli that suppress food intake and potentially engage illness-like
behaviors.

Collectively, the data presented show that central GLP-1 signaling is required for the
anorectic and body weight changes induced by hindbrain 5-HT, an effect that is
mediated, at least in part by the activation of both 5-HT2CR and 5-HT3R expressed on
PPG neurons. Future studies will pursue a more in-depth analysis of other
behavioral/physiological effects that could be influenced by the central interaction
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between 5-HT and GLP-1, as well as try to identify the central source of 5-HT that is
responsible for activation of PPG neurons. Among the caudal nuclei that compose the
Raphe and project to the hindbrain, the Raphe Magnus contains the highest density of 5HT neurons(Charnay and Léger, 2010) and has been shown to project to the
NTS(Basbaum et al, 1978; Thor and Helke, 1989), making for a prime candidate as a
potential upstream regulator of the GLP-1 system. Importantly, our findings set forth 5HT as a novel endogenous modulator of the central GLP-1 system and suggest that the
central interaction between 5-HT and GLP-1 is relevant for the control of food intake.
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Figures

Figure 2.1. Hindbrain administration of 5-HT reduces chow intake and body
weight, while increasing kaolin intake. Treatment with 40µg of 5-HT into the 4th ICV
(n=18) significantly decreases chow intake at 1, 3, 6, and 24 h (a), 24 h body weight (b),
and increased 24 h kaolin intake (c). Data were analyzed employing a paired student’s ttest, the asterisks denote a significant difference between 5-HT and vehicle-treated
animals (**p<0.01, ***p<0.001).
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Figure 2.2. Central blockade of GLP-1R signaling reverses the effects of a
hindbrain administration of 5-HT. Treatment with 5-HT (40 μg, 4th ICV) was followed
by 20 μg of the GLP-1R antagonist, Exendin-9 (Ex9) into the LV (n = 30). This dose of
Ex9 had on its own had no effect on food intake but was able to reverse the anorectic
effects of 5-HT at 1, 3, 6, and 24 h post injection (a) and prevents the reduction in body
weight seen 24 h post injection (b). In a sub-cohort (n = 13) in which kaolin intake was
measured 5-HT increased kaolin intake but treatment with Ex9 did not significantly
attenuate that effect (c). Data were analyzed using a two-way ANOVA, different letters
are significantly different from each other (p < 0.05) according to Newman–Keuls post
hoc analyses.
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Figure 2.3. Expression of 5-HT2CR and 5-HT3R mRNA on rat PPG neurons in the
medial NTS. FISH was conducted on medial NTS sections (20 μm), obtained at the
level of the obex (14.15–14.64mm posterior to bregma) (a), using probes for PPG, 5HT2CR, and 5-HT3R (n=4). A representative NTS section at ×20 magnification is shown
in (b), PPG are shown in blue, 5-HT2CR in magenta, 5-HT3R in green, and DAPI in
gray. The dotted box in b is further magnified (40X) in subpanels, these highlight
colocalization between PPG neurons (top left) with 5-HT2CR (top right), 5-HT3R (bottom
left), or both (bottom right) (b). There is a high degree of heterogeneity in the expression
level of the 5-HTRs on PPG neurons (c). The dotted boxes in c are further magnified (1–
3 optical zoom) in subpanels to the right (subpanels 1–4 correspond to the dotted
boxes), these show individual variability in mRNA expression of 5-HT2CR and 5-HT3R
between PPG neurons About 90% of PPG neurons at this level of the NTS express 5HT2Rs, 62% express 5-HT3R, and 55% co-express both receptors (d) . Representative
three-dimensional rotational video showing colocalization of 5-HT2R and 5-HT3R on
PPG neurons. This video is taken from a z-stack (2 mm step size) collected from the
mNTS at the level of the obex with the × 40 oil-immersion objective and a 2–4 optical
zoom (e).
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Figure 2.4. Activation of hindbrain 5-HT2CR suppresses chow intake without
affecting kaolin intake and is dependent on central GLP-1 signaling. The 5-HT2CR
agonist, Lorcaserin (Lor) was delivered (4th ICV) using the following doses: 0 (aCSF), 2,
10, or 20 μg (a–c) (n = 9). At 1 h post injection all tested doses of Lor reduce chow
intake, at 3 h only the 10 μg and 20 μg doses cause a significant reduction (a). In a
separate cohort (n = 8) the effect of 20 μg Lor (4th ICV) on 24 h BW and kaolin intake
were measured (b–c). At this dose Lor did not affect 24 h body weight (b) nor kaolin
intake (c). Treatment with Ex9 reverses the anorectic effect of Lor seen at 1 and 3 h (d)
(n=20). Lor and Ex9 alone or in combination have no effect on 24 h body weight (e) nor
kaolin intake (f). A repeated measures one-way ANOVA and Dunnet post hoc (*p < 0.05,
**p < 0.01) was used in a, whereas a paired t test was used for b–c. Data in d –f were
analyzed using a two-way ANOVA, different letters are significantly different from each
other (p < 0.05) according to Newman–Keuls post hoc analyses.
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Figure 2.5. Activation of hindbrain 5-HT3R suppresses chow intake and is
dependent on central GLP-1 signaling. The 5-HT3R agonist, SR57227 (SR5) was
delivered (4th ICV) using the following doses: 0 (aCSF), 5, 10, or 20 μg (a–c) (n = 11).
Only the highest dose (20 μg) of SR5 suppresses chow intake, this suppression was
significant at all timepoints (a). A 20 μg treatment with SR5 (4th ICV) prevents BW gain
seen in the control group (b) and increases kaolin intake (c) (n = 21). The effect of
central blockade of GLP-1Rs was tested in a separate cohort (n = 19). Treatment with
Ex9 reverses the anorectic effect of SR5 at 6 and 24h, but not at 1 and 3h (d) (n=19).
SR5 and Ex9 alone or in combination have no effect on 24 h body weight e or kaolin
intake (f). A repeated measures one-way ANOVA and Dunnet post hoc (*p < 0.05, **p <
0.01) was used in a, whereas a paired t test was used for b–c. Data in d –f were
analyzed using a two-way ANOVA, different letters are significantly different from each
other (p < 0.05) according to Newman–Keuls post hoc analyses.
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Figure 2.6. A sub-threshold dose of RS102221 reverses Lorcaserin-induced chow
intake suppression. The 5-HT2CR antagonist, RS102221 (RS1), was administered
(n=16) using the following doses (4th ICV): 0 (aCSF), 10, 20, or 40µg. There was no
effect on chow intake by any of the tested doses (a) Pre-treatment with RS1 (40µg, 4th
ICV) reverses the anorectic effects induced by 20µg of Lor (4th ICV; n=10) at 1h (b). A
repeated measures one-way ANOVA followed by Dunnet’s post-hoc was used in a,
while a two-way ANOVA at each time and Newman-Keuls post-hoc was used in b.
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Figure 2.7. Hindbrain blockade of 5-HT3R, but not 5-HT2CR, reverses the acute
anorectic effects of systemic LiCl. Pre-treatment with the 5-HT3R antagonist, OND
(25 μg; 4 V; n = 14), or the 5-HT2CR antagonist, RS1 (40 μg; 4 V; n = 8), pre-treatment
was followed by LiCl (127.2 mg/kg; i.p). At this dose, LiCl significantly suppresses chow
intake (a) and increases kaolin intake at all timepoints (b) but has no effect on body
weight (c). Pre- treatment with RS1 had no effect d on the LiCl-induced anorexia. The
LiCl-induced suppression of chow intake was attenuated at 1 h and reversed at 3h by
pre-treatment with OND (e). Chow intake was analyzed using a two-way ANOVA at each
timepoint, different letters are significantly different from each other (p < 0.05) according
to Newman–Keuls post hoc analyses.
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Abstract
Within the hindbrain, serotonin (5-HT) functions as a modulator of the central glucagonlike peptide-1 (GLP-1) system. This interaction between 5-HT and GLP-1 is achieved via
5-HT2C and 5-HT3 receptors and is relevant for GLP-1-mediated feeding behavior. The
central GLP-1 system is activated by various stressors, activates the hypothalamic
pituitary adrenocortical (HPA) axis, and contributes to stress-related behaviors. Whether
5-HT modulates GLP-1’s role in the stress response in unknown. We hypothesized that
the serotonergic modulation of GLP-1-producing neurons (i.e., PPG neurons) is stimulispecific and that stressed-induced PPG activity is one of the modalities in which 5-HT
plays a role. In this study, we investigated the roles of 5-HT2C and 5-HT3 receptors in
mediating the activation of PPG neurons in the nucleus tractus solitarius (NTS) following
exposure to three different acute stressors: lithium chloride (LiCl), noncontingent cocaine
(Coc), and novel restraint stress (RES). Results showed that increased c-Fos expression
in PPG neurons following LiCl and RES—but not Coc—is dependent on hindbrain 5HT2C and 5-HT3 receptor signaling. Additionally, stressors that depend on 5-HT
signaling to activate PPG neurons (i.e., LiCl and RES) increased c-Fos expression in 5HT-expressing neurons within the caudal raphe (CR), specifically in the raphe magnus
(RMg). Finally, we showed that RMg neurons innervate NTS PPG neurons and that
some of these PPG neurons lie in close proximity to 5-HT axons, suggesting RMg 5-HTexpressing neurons are the source of 5-HT input responsible for engaging NTS PPG
neurons. Together, these findings identify a direct RMg to NTS pathway responsible for
the modulatory effect of 5-HT on the central GLP-1 system—specifically via activation of
5-HT2C and 5-HT3 receptors—in the facilitation of acute stress responses.
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Introduction
Metabolic neuropeptide systems are influenced by a myriad of biological mechanisms,
including signals not directly linked to energy balance, such as environmental stressors,
anxiogenic factors, and exogenous substances of abuse (e.g., cocaine, alcohol) [for
review see (Gülpinar and Yegen, 2004; Hernandez and Schmidt, 2019; Holt et al, 2016;
Kormos and Gaszner, 2013; Roubos et al, 2012)]. Disentangling the mechanism(s) by
which different stimuli engage converging CNS systems is necessary to design more
efficacious treatments for various clinical conditions, such as metabolic disorders (e.g.,
obesity and eating disorders), substance abuse, and mood disorders (e.g., anxiety and
depression). An example of a metabolic system that is responsive to multiple cues is the
GLP-1 system. In addition to glucoregulation and satiation (Barrera et al, 2011b; Cabou
et al, 2008; Müller et al, 2019), the GLP-1 system plays a role in the behavioral and
physiological response to stress (Ghosal et al, 2013; Herman, 2018; Holt et al, 2016),
nausea/emesis (De Jonghe et al, 2016; Kanoski et al, 2012; Kinzig et al, 2003),
motivated behavior (Alhadeff et al, 2012; Dickson et al, 2012; Hayes and Schmidt, 2016;
Hernandez et al, 2019), inflammation (Lee and Jun, 2016; Que et al, 2019), and
neurogenesis (Athauda and Foltynie, 2016; Bae and Song, 2017; Grieco et al, 2019).
Understanding the heterogeneity of the neural response that engages the GLP-1 system
following exposure to different stimuli is therefore required to discern how the central
GLP-1 system accomplishes its broad range of physiological functions.

The relationship between GLP-1 and stress is of particular interest because of the
pervasive role stress mechanisms play in perturbing homeostasis and the close link that
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exists between stress and pathology. There is a wealth of literature highlighting the
relationship between GLP-1 and stress. Indeed, GLP-1-producing (preproglucagon;
PPG) neurons—expressed almost exclusively in the NTS (Larsen et al, 1997a; Trapp et
al, 2015)—are responsive to a variety of stressors (De Jonghe et al, 2016; Grill et al,
2004; Maniscalco et al, 2015; Rinaman, 1999b; Terrill et al, 2019). The GLP-1 system
engages peripheral and central stress centers, the sympathetic nervous system (Baggio
et al, 2017; Yamamoto et al, 2002) and the hypothalamic-pituitary-adrenal axis (HPA)
(Gil-Lozano et al, 2010; Tauchi et al, 2008a), respectively. Additionally, exogenous
administration of GLP-1 and its agonists increase plasma levels of stress hormones
such as ACTH (Kinzig et al, 2003) and corticosterone (Gil-Lozano et al, 2010; Schmidt et
al, 2016). Further, GLP-1 receptor activation can induce behavioral responses similar to
those invoked by stress including anorexia (Grill et al, 2004; Rinaman, 1999a; Terrill et
al, 2018), anxiety- and depressive-like behaviors (Anderberg et al, 2016; Zheng et al,
2019). Previous efforts to understand the link between stress and the GLP-1 system
have focused on a unidimensional comparison, which assesses the effect of a single
stressor (e.g., LiCl, LPS, restraint, or cocaine) on a single metabolic system (i.e., GLP1). This one-to-one comparison has laid the groundwork for most of what is known about
the GLP-1 system in response to stress, however, it does not address the overlapping
role that other stress/metabolic systems may play.

Serotonin (5-hydroxytryptamine; 5-HT) is implicated in the regulation of stress and
energy balance mechanisms (Bagdy et al, 1989; Heisler et al, 2007; Mikkelsen et al,
2004; Pollock et al, 1981; Tafet and Nemeroff, 2016) and its actions in the hindbrain
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have recently been shown to play a role in the modulation of the central GLP-1 system
(Holt et al, 2017; Leon et al, 2019). Suppression of food intake and body weight, as well
as pica, are the only GLP-1-driven effects that have been shown to depend on hindbrain
5-HT signaling of PPG neurons (Leon et al, 2019). Whether this serotonergic
engagement of the central GLP-1 system is unique to feeding and nausea/malaise or
represents a more ubiquitous relationship that influences other GLP-1-mediated
functions remains to be determined, as does the source(s) of 5-HT that engages the
central GLP-1 system. In this study, we set out to investigate whether 5-HT engages
NTS PPG-neurons in response to different acute stressors and to identify the
serotonergic sub-nucleus responsible for engaging the central GLP-1 system in the
context of stress.

Of the plethora of available acute stressors, lithium chloride (LiCl), cocaine (Coc), and
novel restraint (RES) were chosen for this study because all three stimuli engage the
HPA axis (Bhatnagar and Dallman, 1998; Schmidt et al, 2016; Sugawara et al, 1988),
activate PPG neurons (Rinaman, 1999b; Schmidt et al, 2016; Terrill et al, 2019), and are
different in nature (interoceptive stress, drug of abuse, and psychogenic stress,
respectively). These stimuli represent stressors that have been well characterized within
the GLP-1 literature see (Ghosal et al, 2013; Hayes et al, 2016; Herman, 2018;
Hernandez et al, 2019; Holt et al, 2016; Maniscalco et al, 2017). Of the 5-HTRs
expressed in the NTS, mRNA transcripts for the 5-HT2C and 5-HT3 receptors are
present in PPG neurons (Leon et al, 2019) making them ideal candidates to explore the
5-HT modulation of NTS PPG neurons.
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Within the brain, 5-HT is produced primarily in the raphe nucleus (Berger et al, 2009;
Hornung, 2012), which is comprised of multiple sub-nuclei that are categorized into two
groups based on the orientation of their projections. The rostral raphe projects mostly to
the forebrain and contains approximately 85% of all central 5-HT neurons, while the
caudal raphe (CR) projects mainly to the brainstem and spinal cord and accounts for the
remaining ~15% of central 5-HT neurons (Hornung, 2003). The CR is composed of the
raphe pallidus (RPa), raphe obscurus (ROb), and raphe magnus (RMg). These nuclei
are involved in a wide range of functions including cardiorespiratory, gastrointestinal,
thermoregulatory, and motor control (Lovick, 1997; Ulhoa et al, 2013). Given the
orientation of efferent projections from the caudal vs. rostral raphe and that the NTS lies
caudally from the raphe, we hypothesized that the driver of 5-HT input into NTS PPG
neurons is the CR.

The three main goals of this study are: (1) to assess the modulatory role of hindbrain 5HT2C and 5-HT3 receptors in mediating NTS PPG activity following various stimuli
known to engage stress centers, (2) to investigate whether 5-HT-expressing neurons
within the CR are activated in response to stimuli that engage the central GLP-1 system,
and (3) to determine whether neurons within the CR innervate NTS PPG neurons.
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Materials and Methods
Animals
Male Sprague Dawley rats (275 g BW upon arrival; Charles River) were individually
housed in hanging wire cages maintained at 23°C (12 h light/dark cycle) and given ad
libitum chow (Purina LabDiet 5001) and autoclaved tap water. All procedures were
approved by Institutional Animal Care and Use Committee at the University of
Pennsylvania and were performed according to the guidelines determined by the
National Institutes of Health.

Drugs
Central injections: Serotonin chloride (5-HT; Tocris, 3547) was dissolved in artificial
cerebrospinal fluid (aCSF; Harvard Apparatus, 59–7316). The 5-HT3R antagonist,
ondansetron (OND; Tocris) was dissolved in 100% DMSO to make a 12.5 µg/µl dose
solution. This was delivered into the hindbrain via 4th ventricle (4V) administration at 2 µl
volume (total dose 25 µg). The 5-HT2C antagonist, RS102221 (RS1; Tocris) was
dissolved in 100% DMSO to make a 20 µg/µl dose solution and 2 µl (total dose 40 µg)
was administered (4V).
Systemic injections: Lithium chloride (LiCl) was prepared as a 0.6M solution in 0.9%
sterile saline (sal) and administered intraperitoneally (i.p.) in a volume of 5 ml/kg (total
dose 127.2 mg/kg). Cocaine (Coc) was obtained from the National Institute on Drug
Abuse (Rockville, MD) and prepared into a 15mg/kg solution in 0.9% sal, administered
i.p. in a 1 ml/kg volume (total dose 15 mg/kg).
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Acute Restraint Paradigm
Rats were handled daily for at least 7 d prior to test day. On the day of testing, rats were
removed from their home cages and immediately placed into an adjustable restraint
apparatus (Plas-Labs, 544-RR) for 30 min in individual plastic holding cages (not their
home cage).

Blood Collection and CORT Assay
Blood (~300 ul) from the tail vein was collected (Hare et al, 2014) into Hep-coated tubes
(Microvitte 22043975) and centrifuged for 10 min at 1000 x g. The plasma was then
stored at -80C until processing. For corticosterone (CORT) assessment, samples were
analyzed using a corticosterone enzyme-linked immunoassay (ELISA) (Enzo Scientific,
50658140; detection limit 27 pg/ml) per the manufacturer’s instructions. Sample CORT
concentrations were determined by nonlinear regression from the standard curves. The
mean coefficient of intra-assay variation for all plates was below 4%, this was
determined by calculating the % coefficient of variance (CV) for each triplicate sample
present on each plate and then averaging them. The mean coefficient of inter-assay
variation was 3.91% and was determined by comparing the %CV of Standards 1-5 for
each plate that was run.

Stereotaxic surgery
4Th Ventricle (4V) Cannulation: As previously described (Leon et al, 2019).

Viral Injections: Animals received two viral injections during the same surgery. The first
was a unilateral co-injection (60 nl) of AAV1-Cre (AAV1.hSyn.Cre.WPRE.hGH; Penn
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Vector Core; 3.28 X 1013 GC/mL) and cholera toxin B (CTB)-488 delivered into the RMg
(coordinates: A/P -10.9 mm from Bregma, M/L 0, D/V 10.4 mm). This specific AAV1 is
an anterograde viral tracer with a high rate of transduction in the CNS that exhibits transsynaptic spread properties, jumping a single synapse (Suarez et al, 2018; Zingg et al,
2017). AAV1 was paired with Cre recombinase to increase the efficiency of transneuronal spread (Zingg et al, 2017). CTB was used to validate injection site via the
presence of CTB immunoreactivity the RMg. The second injection was an AAV1-FlextdTomato

(1:2

in

0.1M

sodium

phosphate-buffered

saline,

pH

7.4,

AAV1.CAG.Flex.tdTomato.WPRE.bGH; diluted, 2.80 X 1013 GC/mL, Penn Vector Core)
(Suarez et al, 2018) targeting the NTS (bilateral; 100nl/hemisphere) (coordinates: AP -1
mm form occipital, ML 0, DV 8.2 mm from skull). This second viral injection allows for the
Cre-dependent expression of the orange fluorescent protein tdTomato. The animals
received analgesics (meloxicam, 2 mg/kg s.c.) for 3 consecutive days following surgery.

Immunohistochemistry (IHC)
Hindbrain coronal sections (30 µm) were obtained using a cryostat (Leica, CM3050S),
sections at the level of the NTS (~14.15–14.64 mm posterior to Bregma) and CR (9.214.6 mm posterior to Bregma) were collected, placed in cryoprotectant, and stored at 20°C until use. Briefly, the sections were dehydrated in 50% ethanol (30min at RT),
rinsed in PBS (3X 5 min), incubated in 0.1% sodium borohydride (NaBH4) (20 min at
RT), rinsed in PBS (3X 5 min), and blocked in PBS containing 5% normal donkey serum
(NDS) and 0.2% Triton-X (60 min at RT). Sections were incubated in primary antibodies
overnight at RT and, following three rinses in PBS, were incubated in secondary
antibodies for 2h at RT. The primary antibodies used were rabbit anti-GLP-1 (1:2000; T59

4363, Peninsula Laboratories), mouse anti-c-Fos (1:500; sc-271243; Santa Cruz),
donkey anti-5-HT (1:500; ab66047; ABCAM), and mouse anti-beta subunit Cholera
Toxin (1:500; ab62429; ABCAM). Secondary antibodies were donkey anti-rabbit Alexa
Fluor 594 (1:500), donkey anti-mouse Alexa Fluor 488 (1:500), and donkey anti-donkey
Alexa Fluor 405 (1:500) (all from Jackson Immuno Research). Sections were mounted
onto glass slides (Fisher), coversliped with mounting media, and the edges sealed with
nail polish. Slides were stored at 4oC until imaged.

Dual Fluorescent In-Situ Hybridization and Immunohistochemistry
Tissue preparation: Perfused hindbrain sections containing the NTS were used to
perform FISH using a commercially available kit (Cat. No. 323100, RNAscope Multiplex
Fluorescent v2 Assay, Advanced Cell Diagnostics).

FISH mRNA expression of PPG in the NTS. NTS sections stored in cryoprotectant at 20°C were rinsed in PBS and slide mounted. Following a 5min PBS rinse the slides were
incubated for 30 min at 60oC in the HybEZTM oven (ACD) and then post-fixed in 10%
NBF for 15 min at 4oC. The sections were dehydrated in ascending ethanol solutions (5
min washes in 50, 70, 100, 100% ethanol). After the second 100% ethanol wash the
slides were air-dried and a hydrophobic barrier was created on the slide surrounding the
sections. The sections were treated with 0.3% H2O2 for 10min at RT, followed by diH20
washes (3X 1min). After the last rinse, the slides were transferred into a diH20 wash
inside a steamer (temp >99°C) for 10s to acclimate before being incubated in the Target
Retrieval Reagent (TRR; PN 322000) for 5min (also inside the steamer). The sections
were removed from the steamer, rinsed in diH20, incubated in 100% ethanol for 3 min,
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and then air dried for 5 min at RT. The sections were incubated with Protease III (PN
322337) for 30 min at 40oC followed by diH20 washes (2X). Sections were then
immediately incubated for 2h at 40oC using a probe designed by ACD to label PPG
mRNA (Rn-GcgsC3; 315471-C3). Following rinses in 1X wash buffer (PN 310091) (2X 2
min) the sections went through a series of amplification steps at 40oC: 30min incubation
in FL v2 AMP1, 30min incubation in FL v2 AMP2, 15min incubation in FL v2 AMP3 (with
two rinses in wash buffer between each step). Following the amplification steps the
sections were incubated in the Multiplex FL v2 HRP-C3 at 40oC for 15 min and then
rinsed wash buffer (2X). The sections were then incubated in opal dye 690 (diluted
1:1000) at 40oC for 30 min, rinsed in wash buffer (2X), and then incubated with FLv2
HRP blocker for 15min at 40oC. The sections were rinsed one last time before starting
the immunohistochemical processing.

IHC to visualize 5-HT fibers in NTS sections. The IHC protocol was similar to the
description above, the only difference was the concentration of the blocking solution
(PBS containing 3% normal donkey serum and 0.3% Triton-X) and the incubation with
primary antibodies was done at 4oC.

Image acquisition, processing, and quantification. Sections were visualized with a Leica
SP5 X confocal microscope using the 20 and 40 oil- immersion objectives and the 405,
488, 594, and 647 laser lines. Image z-stacks with the 40 oil-immersion were collected
with a step size of 1 µm, while 2–3 optical zoom z-stack images using the same
objective were collected with a step size of 0.5µm. All images were collected
sequentially to avoid contamination of signals from other fluorophores. Co-localization of
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PPG neurons and TD-Tom positive neurons was quantified manually on Imaris following
background subtraction. Three-dimensional rotational animations were rendered from
the collected z-stack images using Imaris 9.5.0 (Bitplane).

Statistical analyses
All data are represented as mean ± SEM. Data were analyzed using either a two-way
ANOVA, one-way ANOVA, or an unpaired t-test (specific for each dataset). Statistically
significant effects were probed using either Bonferroni or Tukey post hoc analysis. For
all statistical tests, a p-value less than 0.05 was considered significant.

Experimental procedures
Experiment 1: Effects of different stimuli on plasma levels of CORT. Three different
cohorts of animals were used. The first compared Sal, LiCl, and Coc (n=15); the second
examined RES vs. no RES (n=12); the third compared 4V administration of 5-HT and
aCSF (n=8). Testing for all cohorts began at ~1 hr before dark onset. Following an initial
baseline blood drawn, rats were exposed to one of the following treatments: 30 min of
novel restraint (RES), no RES, LiCl (127.2 mg/kg; i.p.), Coc (15 mg/kg; i.p.), Sal (5
ml/kg; i.p.), 5-HT (40µg; 4V), or aCSF (1 µl; 4V). Additional blood draws were conducted
30- and 60-min post stimuli exposure. In the case of RES, the blood draws were prior to
the start of restraint (0 min), right after the end of the 30 min restraint session (30 min),
and after 30 min of being back in their home cage (60 min). The blood was processed
for CORT measurements as described in the method section 2.4.
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Experiment 2: Effect of hindbrain 5-HTR blockade on c-Fos expression on NTS PPG
neurons following LiCl, cocaine, and novel restraint. Male rats (n=30) were pre-treated
with 4V injections of the 5-HT2C receptor antagonist (RS1; 40µg), the 5-HT3 receptor
antagonist (OND; 25 µg), or 100% DMSO (vehicle; 2 µl). These doses were chosen
because they do not have an effect on food intake on their own but do block the intake
suppressive effects of 5-HT (Leon et al, 2019). Given that these drugs were delivered
into a ventricle, instead of the parenchyma, the volume used (2 µl) is within acceptable
range as to not cause damage (Harris, 2017; Hayes et al, 2011; Noble et al, 2018).
Fifteen minutes following 4V injections the animals were exposed to either a systemic
injection of LiCl (127.2 mg/kg), Coc (15 mg/kg), or Sal (5ml/kg; vehicle). The animals
were transcardially perfused 75min later and IHC analysis was conducted on caudal and
mid NTS sections (14.2-15.7mm posterior to bregma) looking at co-localization between
c-Fos (i.e. marker of neuronal activation) and GLP-1 immunoreactivity. Co-localization
was quantified manually using Image J. A separate cohort was used to analyze the
effects of 5-THR antagonists on PPG activity induced by novel restraint (RES) (Terrill et
al, 2019). Fifteen minutes following 4V injections of 100% DMSO (veh), RS1, OND, or
RS1+OND (Combo) male rats (n=33) were exposed to 30 min of novel restraint (RES)
(methods section 2.4), the control groups were left uninterrupted in their cage for 30min
(no RES). Similar to the previous cohort, the animals were transcardially perfused 75
min later and IHC analysis was conducted.

Experiment 3: Changes in c-Fos expression within the CR in response to LiCl, cocaine,
and novel restraint. Three separate cohorts were used to assess the effects of LiCl
(n=12), Coc (n=8), or RES (n=10) on c-Fos expression in the CR. Seventy-five minutes
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after being exposed to either LiCl (or Sal), Coc (or Sal), or RES (or no RES) the animals
were transcardially perfused and the brainstems were harvested and sectioned. Brain
sections containing the RPa, ROb, and RMg (-9.6-13.5mm posterior to bregma) were
collected and mounted. IHC analyses was performed to determine 1) neuronal activity in
the CR subnuclei by assessing total changes in c-Fos expression and 2) correlation
between neuronal activity (i.e. total c-Fos expression) and activation of 5-HT neurons in
the CR subnuclei by quantifying co-localization between c-Fos and 5-HT positive
neurons. In both cases, manual quantification of immunoreactive cells was conducted for
each of the three sub-nuclei that make up the CR (RPa, ROb, and RMg) (n=3-5 sections
per condition), these individual values were then combined to get an assessment of the
entire CR (labeled in figures as Total CR). Total c-Fos and c-Fos/5-HT co-localization
were quantified manually using Image J.

Experiment 4: Monosynaptic viral tracing from the RMg to the NTS. Male rats (n=18 rats;
6 controls and 12 dual injections) received two viral injections (described above). Three
weeks following the viral injections the animals were transcardially perfused and brains
processed as described above. The site of the AAV1-Cre injection was verified using an
anti-CTB antibody in the RMg, only animals that showed CTB immunoreactivity that
exclusively localized within the RMg (i.e., positive control for accurate viral injection)
were included (4 out of 12) in the analysis. A dual FISH/IHC protocol using an RNA
probe for PPG neurons and a 5-HT antibody was used to assess monosynaptic
projections from the RMg to NTS PPG neurons and proximity to 5-HT fibers.
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Results
Plasma corticosterone levels are increased to comparable degrees following exposure to
LiCl, cocaine, and novel restraint.
The stimuli employed in this study—namely LiCl, cocaine (Coc), and novel restraint
(RES)—have all been shown to activate the central GLP-1 system and engage stress
centers (Rinaman, 1999b; Schmidt et al, 2016; Terrill et al, 2019; Vahl et al, 2005). In
order to properly categorize these three different stimuli as “stressors” in the current
studies, we assessed their effects on plasma levels of corticosterone (CORT) (Fig. 3.1).
Baseline levels of plasma CORT (0 min) did not differ between experimental and their
relative control groups for any of the tested stimuli (Fig. 3.1 a-c). The first cohort of
animals compared the effects of i.p. administration of Sal, LiCl, and Coc. There was a
significant effect of time (F1,20≥17.91; p<0.0001), stimuli (F2,12≥4.315; p<0.05), and
interaction (F4,24≥6.533; p<0.01). At 30min, plasma CORT of the LiCl and Coc groups
were significantly higher when compared to the Sal group, p=0.0027 and 0.0481
respectively. At 60min, there was no significant difference between any of the groups,
though there was a clear trend for the LiCl group (p=0.0557; represented with # on the
graph) (Fig. 3.1a). In the novel restraint cohort, there was a significant effect of time
(F2,20≥33.69; p<0.0001), stimuli (F1,10≥21.75; p<0.001), and interaction (F2,20≥6.533;
p<0.01). The RES group had significantly higher CORT levels than the No RES group at
30min (p<0.0001) and 60min (p=0.0389) (Fig. 3.1b). It is worth noting, however, that the
CORT levels for the RES group dropped significantly between 30 and 60min (p=0.0069),
which is supported by the literature (Vahl et al, 2005).
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All three stimuli tested significantly increased plasma levels of CORT at the 30min
timepoint. In order to provide a reference of the magnitude of relative CORT increase, 5HT was infused centrally in a third cohort of rats. In the 5-HT cohort, there was a
significant effect of time (F2,12≥4.14; p<0.05) and stimuli (F1,6≥134; p<0.001) but not of
interaction (F2,12≥2.934; p=0.0918). When compared to its control, 5-HT increased
plasma CORT at 30 and 60min, p=0.0011 and 0.0036 respectively (Fig. 3.1c). When we
compared CORT levels induced by all 4 different stimuli, the degree to which 5-HT
increases CORT (at 30-min post exposure), is significantly higher than the increase
induced by LiCl, Coc, or RES, while no significant differences was observed between the
latter 3 stimuli (Fig. 3.1d).

Pharmacological blockade of hindbrain 5-HT2C and 5-HT3 receptors decrease c-Fos in
NTS PPG neurons following LiCl and novel restraint.
Here we set out to investigate the role of 5-HT2C and 5-HT3 receptors in mediating cFos expression in NTS PPG neurons following diverse acute stressors known to activate
PPG neurons. To assess this, animals pre-treated with pharmacological antagonists for
the 5-HT2CR (RS1) or the 5-HT3R (OND) were exposed to either LiCl, Coc, or RES.
IHC analysis was then used to quantify changes in c-Fos and its co-localization with
PPG neurons.

As expected, LiCl (magenta), Coc (blue), and RES (green) all increased total NTS c-Fos
expression (all p<0.001, Fig. 3.2a, 3.2d, 3.2g) as well as activation of PPG neurons
indicated by an increase in co-localization between c-Fos and GLP-1 immunoreactivity
(all p<0.01, Fig. 3.2b, 3.2e, 3.2h). Administration of either antagonist, OND or RS1, had
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no significant effect on total c-Fos expression (Fig. 3.2a, 3.2d, 3.2g) or on c-Fos/GLP-1
co-localization (Fig. 3.2b, 3.2e, 3.2h) on its own. In the LiCl-treated groups, there was a
significant interaction between LiCl and the 5-HTR antagonists in the total expression of
c-Fos (F2,14≥6.68; p<0.01) and in the PPG/c-Fos co-localization (F2,14≥6.63; p<0.01).
Post hoc analyses revealed that treatment with either antagonist (OND or RS1) was
sufficient to reverse the increase in total NTS c-Fos expression (Fig. 3.2a) as well as the
increased c-Fos/GLP-1 co-localization (Fig. 3.2b-c). A zoomed-out image of the colocalization between PPG and c-Fos immunoreactivity can be found in Fig. 3.3a.

In the Coc groups, there was a significant interaction between Coc and the 5-HTR
antagonists in the total expression of c-Fos (F2,14≥7.21; p<0.01). This degree of
interaction was not detected in the co-localization between PPG and c-Fos
immunoreactivity. Treatment with either 5-HTR antagonist reversed the increase in NTS
c-Fos expression (Fig. 3.2d), but the increase in c-Fos/GLP-1 co-localization was
unaffected (Fig. 3.2e-f; 3.3b). In the RES cohort, there was a significant interaction
between RES and the 5-HTR antagonists in the co-localization between PPG and c-Fos
immunoreactivity (F2,21≥5.00; p<0.05), but not in the total expression of c-Fos. Although
neither antagonist caused a significant effect on total NTS c-Fos expression (Fig. 3.2g),
PPG activity was attenuated by pre-treatment with either OND or RS1 (Fig. 3.2h-i;
3.3c). Animals that received the combo treatment (OND+RS1) did not see an additive
effect in the attenuation of PPG activity. In fact, the attenuation in c-Fos/GLP-1 colocalization seen in the combo treated group (OND+RS1) was indistinguishable from the
animals treated with a single antagonist (Fig. 3.4). Raw cell count of PPG, c-Fos, and
co-localization of immunopositive neurons can be found in Fig. 3.5 (Table 1). These
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results indicate that hindbrain 5-HT2C and 5-HT3 receptors play a role in mediating cFos expression in PPG neurons induced by LiCl and restraint but not cocaine supporting
our hypothesis that the serotonergic modulation of the GLP-1 system is stimulus
specific.

LiCl and novel restraint stress increase c-Fos expression in the RMg.
Next, we aimed to identify the potential source of 5-HT input responsible for engaging
the GLP-1 system. Given the location of the NTS along the rostral-caudal plane and the
orientation of efferent projections emerging from the raphe, we focused on the CR—and
it’s three sub-nuclei (Fig 3.6a)—as the potential source of 5-HT input responsible for
engaging the central GLP-1 system. Total c-Fos expression was quantified in the RPa,
ROb, and RMg (total CR = RPa + ROb + RMg) of animals that had been treated with
LiCl, Coc, or RES.

LiCl increased total c-Fos expression in the CR (total CR) (p<0.01, Fig. 3.6b). A closer
analysis revealed that the RMg drove this effect as it was the only sub-nuclei in which cFos expression was significantly elevated (p<0.01). The ROb and RPa had comparable
c-Fos expression levels in the LiCl- and vehicle-treated animals (Fig. 3.6b). A single
unsolicited Coc administration did not cause any changes in c-Fos expression in any of
the three CR sub-nuclei (Fig. 3.6c). Similar to LiCl’s effects, RES also caused an
increase in total c-Fos expression in the CR (total CR), again a RMg-driven effect
(p<0.05) (Fig. 3.6d). These data suggest that the CR, specifically the RMg, is responsive
to two stimuli that engage the GLP-1 system, namely LiCl and RES. This interpretation is
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supported by our NTS data showing that 5-HTRs in the NTS mediate the activation of
PPG neurons induced by LiCl and RES but not Coc.

LiCl and novel restraint increase c-Fos expression in 5-HT neurons within the RMg.
Next, we tested whether the increase in c-Fos expression observed in the CR correlates
with an increase in activation of 5-HT-expressing neurons. Co-localization between cFos and 5-HT immunoreactive cells in the CR was significantly increased in the LiCl
group (Total CR) when compared to the control group (p<0.01, Fig. 3.7a). When
analyzed individually, the c-Fos/5-HT colocalization in the LiCl treated brains was
significantly higher in the RMg (p<0.005), but no difference was observed in the RPa or
the ROb (Fig. 3.7a-b). A zoomed-out image of the co-localization between 5-HT and cFos immunoreactivity can be found in Fig. 3.8a. In the Coc group, there was no
difference in the c-Fos/5-HT co-localization between the experimental and control
groups in any of the CR sub-nuclei (Fig. 3.7c-d; 3.8b). The RES group saw a similar
pattern to the LiCl group. There was a significant increase in c-Fos/5-HT co-localization
in the CR (Total CR) (p<0.05, Fig. 3.7e). The RMg experienced an increase in c-Fos/5HT colocalization following restraint (p<0.05), but no difference was observed in the RPa
or the ROb (Fig. 3.7e-f; 3.8c). Raw cell count of 5-HT, c-Fos, and co-localization of
immunopositive neurons can be found in Fig. 3.9 (Table 2). Our data show that LiCl and
RES engage the CR and increase activation of 5-HT neurons as read out by c-Fos,
specifically in the RMg, identifying the RMg as the potential source of 5-HT input into
NTS PPG neurons.

Tracing mono-synaptic projections from the RMg to the NTS.
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Male rats (n=18) received an anterograde tracer expressing Cre recombinase
(AAV1.hSyn.Cre.WPRE.hGH) in combination with CTB-488 (used to validate injection
site) into the RMg (Fig. 3.10a, top left) and an AAV1 expressing Cre recombinasedependent TD-Tomato

(AAV1.CAG.Flex.tdTomate. WPRE.bGH) into the NTS (Fig.

3.10a, top right) to determine whether RMg neurons directly innervate NTS PPG
neurons. AAV1 exhibits anterograde trans-synaptic spread properties, jumping a single
synapse (Suarez et al, 2018; Zingg et al, 2017). This allows for viral particles taken up
by neurons in the RMg to travel anterogradely down the axon and be transported onto
downstream neurons, ultimately culminating in the expression of Cre recombinase in
post-synaptic neurons. Cre recombinase-dependent TD-Tomato presence in the NTS
allows for fluorescent tagging of NTS neurons that receive mono-synaptic projections
from the RMg (Fig. 3.10a, bottom right).

A series of different controls were first used for validation of our methods. The top panel
in Fig. 3.10b shows our AAV1-Cre-positive controls animals (n=3), this group received
the AAV1-Cre but not the Cre recombinase-dependent TD-Tomato. The accuracy of the
injection site was corroborated by CTB immunoreactivity in the RMg (green). The lack of
fluorescent signal in the NTS is expected as this group was not injected with
AAV1.CAG.Flex.tdTomate.WPRE.bGH. The middle panel in Fig. 3.10b depicts a
representative

section

of

another

AAV1.CAG.Flex.tdTomate.WPRE.bGH

control

injection

group,
in

the

which
NTS

received
but

no

AAV1.hSyn.Cre.WPRE.hGH in the RMg (n=3). This group lacked both CTB presence in
the RMg and TD-Tomato signal in the NTS, the latter corroborates that the expression
TD-Tomato depends on the presence of AAV1-Cre. Finally, the bottom panel in Fig.
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3.10b is showing a representative image of the RMg and NTS of animals that received
both viral injections. Accuracy of the AAV1 Cre injection into the RMg was confined via
CTB immunoreactivity, only animals in which CTB immunoreactivity was confined to the
RMg were used in the analysis (4 out of 12) (Fig. 3.11). The presence of TD-Tomatopositive neurons in the NTS confirm the presence of a mono-synaptic connection from
the RMg to the NTS and shows a lack of bleed-through of TD-Tomato into other
channels. These results validate our methods demonstrating our ability to successfully
trace direct synaptic connections from the RMg to the NTS.

NTS PPG neurons that receive mono-synaptic projections from the RMg lie in close
proximity to 5-HT axons.
Next, we examined whether RMg neurons project mono-synaptically to PPG neurons.
NTS sections from animals that accurately received both viral injections (n=4) were
processed for FISH/IHC using a mRNA probe for PPG neurons (green) and a 5-HT
antibody (blue) (Fig. 3.12). Following tissue processing required for the FISH/IHC
protocol, the presence of TD-Tomato signal was visible and did not bleed into the other
channels (Fig. 3.12b, NTS on bottom panel). At this rostral-caudal plane, 5-HT fibers
were observed to preferentially target the NTS (Fig. 3.13).

TD-Tomato positive cells (red) were identified in at every rostral-caudal plane we
analyzed, AP-level, obex, and post-obex, as were neurons that showed PPG and TDTomato co-localization (Fig. 3.12a-d). While there was a significant degree of colocalization, not every NTS neuron that received RMg input was PPG. Likewise, not
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every PPG neuron receives monosynaptic input from the RMg. Quantification of
PPG/TD-Tomato

co-localization

revealed

that

43%

of

PPG

neurons

receive

monosynaptic input from RMg neurons, with the obex-level sections showing 37% colocalization, and the post-obex (caudal to obex) sections showing a 50% co-localization
and (data were calculated as average expression per animal) (Fig. 3.12e). The low
number of PPG neurons present at the AP-level of the NTS did not allow for proper
quantification at this plane. There was no significant difference in PPG/TD-Tomato colocalization between hemispheres nor in the rostral-caudal, or medial-lateral planes. A
subset of PPG neurons that co-localize with TD-Tomato were found to be in close
proximity to 5-HT axons (Fig. 3.12d), this was corroborated with a three-dimensional
rotation video of 40×z-stack overlays (Fig. 3.12d, subpanel 2; Video 2). Combined,
these results suggest that the RMg projects mono-synaptically to NTS PPG neurons and
that some of these projections may be from a 5-HT input.
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Discussion
In this study we investigated whether different stressors engage the central GLP-1
system via 5-HT2CR and 5-HT3R signaling. Our results showed that activation of NTS
PPG neurons following exposure to LiCl and novel restraint is dependent on 5-HT2CR
and 5-HT3R signaling, whereas cocaine-induced activation of PPG neurons does not
appear to rely on a hindbrain serotonergic mechanism. Changes in c-Fos expression
within the CR identified the RMg as a potential source of 5-HT input into NTS PPG
neurons. Finally, employing a viral tracing technique we showed that NTS PPG neurons
are innervated directly by RMg neurons and that a sub-set of these neurons are in close
proximity to 5-HT axons. These results support the hypothesis that the modulatory effect
of 5-HT on the GLP-1 system extends beyond the realm of feeding to include modulation
of PPG activity following some, but not all, acute stressors.

Effect of LiCl, cocaine, and novel restraint on plasma levels of CORT.
The increase in plasma CORT observed following LiCl, Coc, and RES provides a
readout corroborating that these manipulations significantly increase levels of stress
hormones and as such can be referred to as “stressors”. These data are supported by
other groups that have found similar results (Hare et al, 2014; Schmidt et al, 2016;
Sugawara et al, 1988). Further, a direct comparison of CORT levels at 30min across
experimental groups revealed that LiCl, Coc, and RES elevate CORT to comparable
levels (~150-200ng/ml). These results suggest that all three acute stressors employed in
this study produce a similar release of CORT and on a comparable timeline, thus
providing validity for the comparison of neuronal activity induced by these three stimuli.
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Despite the congruence in levels of elevated CORT at 30min, there are differences in
the overall temporal CORT response induced by these different stressors. Despite not
reaching significance it is worth noting that the LiCl-treated animals showed a trend
towards increased CORT at 60 min (p=0.0557) when compared to its control. It is likely
that CORT levels induced by LiCl continue to increase after the 30 min of exposure. In
fact, one study showed increase CORT up to 2 h post LiCl injection (Jacobs, 1978). The
difference observed in our study could be due to differences in experimental design or
individual variability. The effect of Coc on CORT levels is pronounced but short-lived,
60min post injection CORT levels were on par with the control group. Despite the
increased CORT levels observed in the RES group at 60 min, this value was significantly
lower than CORT levels measured at 30min. This is supported by the literature (Vahl et
al, 2005) which indicates that CORT levels following novel restraint of 30 min peaks
immediately after the animals are removed from the restraint apparatus.

Effect of hindbrain 5-HT2C and 5-HT3 receptors in mediating LiCl-induced PPG activity.
LiCl is a well-established model of interoceptive stress, it induces pro-inflammatory
effects and mimics patho-physiological (e.g. inhibition of gastric motility) and behavioral
responses (e.g. anorexia) observed during systemic malaise (Kinzig et al, 2003; Kinzig
et al, 2008; Koehnle and Rinaman, 2010; McCann et al, 1989; Nassar and Azab, 2014;
Rinaman, 1999a, b; Sugawara et al, 1988). While the exact mechanisms through which
LiCl engages stress centers remains elusive, activity of the GLP-1 (Rinaman, 1999a, b)
and 5-HT (Limebeer et al, 2018; Sheard and Aghajanian, 1970) systems are both
enhanced following systemic LiCl. The impact LiCl has on the central 5-HT system has
74

been predominantly studied in forebrain structures (Limebeer et al, 2018; Sheard et al,
1970). To the best of our knowledge, the effect LiCl has on hindbrain 5-HT activity or the
relationship this effect may have on the central GLP-1 system has not previously been
studied.

In this study we showed that pharmacological blockade of hindbrain 5-HT2CRs or 5HT3Rs was sufficient to block the LiCl-induced increase in total NTS c-Fos expression
as well as the PPG/c-Fos co-localization. This indicates that hindbrain 5-HT2CRs and 5HT3Rs mediate LiCl-induced PPG activation and are significant drivers of total NTS
neuronal activity following LiCl. While it remains to be confirmed, this newfound
association between 5-HT and GLP-1 likely underlies some of the behavioral effects
induced by LiCl, such as hypophagia and malaise. Support for this comes from studies
showing that systemic 5-HT3R antagonism reduces LiCl-induced gaping (i.e. a marker of
visceral malaise) (Rock and Parker, 2013) and hindbrain 5-HT3R blockade reverses the
acute anorectic effect (Leon et al, 2019) of LiCl. Additionally, blockade of GLP-1Rs
attenuate LiCl-induced hypophagia (Rinaman, 1999a) and pica (i.e. kaolin consumption,
a validated proxy for malaise) (Seeley et al, 2000). The ability of LiCl to activate the HPA
axis and increase plasma levels of stress hormones (Jahng and Lee, 2015) could be
explained by the engagement of the HPA via GLP-1 signaling, given that PPG neurons
activated by LiCl project to the PVN (Rinaman, 1999b) and that central GLP-1 increases
both ACTH and CORT levels (Kinzig et al, 2003). We have identified that LiCl engages
the GLP-1 system via hindbrain 5-HTRs and discussed how this interaction may play a
role in the behavioral and mechanistic stress response elicited by LiCl. However, future
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studies are required to decipher the mechanism through which LiCl activates the 5-HT
system.

Effect of hindbrain 5-HT2C and 5-HT3 receptors in mediating PPG activity induced by
novel restraint.
Unlike LiCl, psychogenic stressors—such as acute, novel restraint—are not physically
painful and thus rely on the perception of a threat (Doremus-Fitzwater et al, 2009;
Herman and Cullinan, 1997). Restraint activates PPG neurons (Maniscalco et al, 2015;
Terrill et al, 2019) and increases brain levels of 5-HT (McIntyre et al, 1999; Mo et al,
2008). Here, we show that blockade of hindbrain 5-HT2CRs and/or 5-HT3Rs attenuates
the activation of PPG neurons induced by novel restraint without affecting total NTS
neuronal activity. This indicates that hindbrain 5-HT2CRs and 5-HT3Rs play a role in
mediating the specific engagement of the central GLP-1 system following exposure to
novel restraint. The attenuation of RES-mediated PPG activity in the RS1+OND combo
group was comparable to animals that received individual treatment of either antagonist.
The observed lack of additive/synergistic effect could be explained by the significant
overlap of 5-HT2C and 5-HT3 receptor expression among PPG neuronal populations. In
fact, ~90% of PPG neurons express the 5-HT2C receptor and over 50% of PPG neurons
co-express both the 5-HT2C and 5-HT3 receptors. Considering this degree of overlap,
manipulation of either receptor type alone may be sufficient to engage the central GLP-1
system. There are two additional points worth discussing in more detail. First, in
response to novel restraint— in contrast to LiCl— PPG activation is only partially
dependent on hindbrain 5-HT signaling. Given the complexity of psychogenic stressors,
it’s not too surprising that a single system (i.e., 5-HT) does not have an all-or-nothing
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effect on the neuronal activity produced by novel restraint. Second, the lack of effect on
total NTS neuronal activity (total c-Fos) indicates that a significant portion of NTS
neurons activated by novel restraint are not PPG in nature. This is substantiated by the
inability of RS1 to significantly attenuate total NTS c-Fos expression despite 5-HT2CRs
being present on ~90% of PPG neurons (Leon et al, 2019). Both points—partial
dependence on 5-HT and RES activating non-PPG neurons—can be addressed by
reports indicating that restraint engages other neuronal populations within the NTS, most
notably noradrenergic neurons (Bundzikova-Osacka et al, 2015; Maniscalco et al, 2012).
The lack of effect on total NTS c-Fos expression in response to 5-HT2CR and 5-HT3R
blockade could result from restraint activating other neuronal populations within the NTS.
This could also help explain the inability of hindbrain 5-HTR blockade to fully reverse
RES-induced PPG activity as it is possible that PPG activation is a second- or third-order
response to novel restraint. In one scenario, novel restraint could be engaging NTS
neurons (e.g. NA, Glu) which then activate PPG neurons. However, it’s also possible
that novel restraint engages PPG neurons via forebrain mechanisms such as projections
from the central nucleus of the amygdala (Mohammad et al, 2000; Saha, 2005). The
involvement of the 5-HT/GLP-1 interaction in mediating restraint-induced PPG activity
opens the door to many questions regarding its role in modulating the physiological
response to other psychogenic stressors [e.g. social defeat (Razzoli et al, 2015)].

Cocaine-induced PPG activity is not mediated by hindbrain 5-HT2C and 5-HT3
receptors.
Despite their rewarding properties, drugs of abuse—such as ethanol, cocaine, and
methamphetamine—cause aversive-like behaviors in rodents when administered in a
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non-contingent manner as was done in this study (Davies and Parker, 1990; Parker,
1993; Turenne et al, 1996). While cocaine is not considered a traditional stressor, its
acute administration engages stress centers such as the HPA axis and increases
plasma ACTH and CORT (Cleck and Blendy, 2008; Manetti et al, 2014; Schmidt et al,
2016). Cocaine engages the central GLP-1 and 5-HT systems, it increases endogenous
5-HT in the ventral pallidum (Matsui and Alvarez, 2018) and activates NTS PPG neurons
(Schmidt et al, 2016). Additionally, GLP-1Rs in the ventral tegmental area (Hernandez et
al, 2018) and nucleus accumbens (Hernandez et al, 2019) have been implicated in
mediating cocaine-seeking behavior in rats. Our results showed that hindbrain blockade
of either the 5-HT2CR or 5-HT3R following an acute noncontingent systemic infusion of
cocaine attenuates total neuronal activation within the NTS but has no effect on the
specific activation of PPG neurons. This indicates that hindbrain 5-HT2C and 5-HT3
receptors do not mediate cocaine-induced activation of PPG neurons, however, they do
play a role in mediating cocaine’s actions on NTS neuronal activity, via a non-PPG
mechanisms. It would be of interest in future studies to characterize the NTS neuronal
population that is engaged by cocaine and susceptible to 5-HT modulation. Although the
mechanism(s) through which cocaine engages PPG neurons remains unclear,
glucocorticoids appear to be an attractive candidate. Schmidt et al showed that central
administration of CORT attenuates cocaine self-administration, this effect was blocked
by pretreatment with the GLP-1R antagonist, exendin (9-39) (Schmidt et al, 2016).
Additionally, glucocorticoid receptors (GRs) are expressed extensively in the NTS
(Härfstrand et al, 1986; Herman, 1993) and, thus, are likely to be present on PPG
neurons. However, future experiments are needed to test this hypothesis.

78

Potential source of 5-HT driving engagement of NTS PPG neurons.
Identifying the source of 5-HT responsible for mediating GLP-1 signaling is critical in
better understanding how these two systems interact and the range of biological
influence this interaction may have. Of the CR sub-nuclei, we focused on the RMg given
that it contains the highest level of 5-HT neurons (Hornung, 2003). Here we showed that
LiCl and novel restraint (stressors that require 5-HT2C and 5-HT3 receptors in order to
engage NTS PPG neurons) increased total neuronal activity in the CR. This effect was
driven by the RMg and correlated with an increase in 5-HT neuronal activity. This
neuronal responsivity indicates that the CR, specifically the RMg, is engaged by
stressors that activate the GLP-1 system. These data identify the RMg as a potential
source of 5-HT responsible for modulating the central GLP-1 system—at least in
response to certain stressful stimuli.

The RMg is known to project to the NTS (Thor et al, 1989), however, the neuronal
population(s) it targeted remained unknown. Combining the viral tracing with a FISH/IHC
protocol we showed that 43% of NTS PPG neurons receive mono-synaptic projections
from the RMg. Additionally, we found a sub-set that were in close opposition to 5-HT
axons. This suggests that at least a portion of the RMg input into NTS PPG neurons
comes from a 5-HT source. A direct connection between PPG neurons and 5-HT fibers
can only be confirmed using electron microscopy (EM) and remains a topic for future
studies. In addition to confirming a direct synaptic connection between RMg 5-HT
neurons and NTS PPG neurons it would be of interest to assess the behavioral
relevance of 5-HT input onto PPG neurons on feeding or other stress-mediated
79

responses. Assessing whether the interaction between 5-HT and GLP-1 is preserved
between sexes was not addressed in this study and remains to be determined. Given
the species-specific differences between mice and rats in regard to the central GLP-1
system (Cork et al, 2015; Lachey et al, 2005), it would be important to conduct
electrophysiological studies aimed at characterizing the direct impact of 5-HT receptor
activation on activity of NTS PPG neurons in rats once PPG-Cre transgenic rat lines
become available.

Collectively, our results indicate that LiCl and novel restraint activate 5-HT neurons in
the RMg of the CR and require 5-HT2C and 5-HT3 receptor signaling in the NTS in order
to engage the central GLP-1 system. The stressors chosen in this study are different in
nature and thus provide solid support for the idea that 5-HT modulates GLP-1 in
response to stress. However, given that acute and chronic stress generate different
neuroendocrine responses and, in some instances, opposing effects on feeding behavior
(Rabasa and Dickson, 2016), it would be of interest to investigate whether the
modulatory effect 5-HT has on central GLP-1 changes under long-term exposure to
stress. While this study focused on 5-HT2C and 5-HT3 receptors, the role of other 5-HT
receptor subtypes and their ability to modulate PPG activity following acute and chronic
exposure to stress still needs to be investigated. In particular the 5-HT2A receptor, given
its presence in the NTS (Hosford et al, 2015) and its well-established role in stressrelated disorders including depression and post-traumatic stress disorder (Carr and
Lucki, 2011; Murnane, 2019; Nutt, 2015).
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Conclusion.
Taken together, the NTS and CR data indicate that hindbrain 5-HT signaling—putatively
originating in the RMg—acting through 5-HT2C and 5-HT3 receptors expressed on NTS
PPG neurons mediate the neural activation of PPG neurons by LiCl and novel restraint,
but not cocaine. These results support our initial hypothesis and show that the
relationship between 5-HT and GLP-1 is not only relevant in the context of feeding (Leon
et al, 2019), but that 5-HT also mediates GLP-1 in response to different acute stressors.
The ability of 5-HT to control NTS PPG activity in response to different stressors
highlights complexity and multidimensional nature of the central 5-HT/GLP-1 interaction.
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Figures

Figure 3.1. Changes in circulating CORT levels in response to different stimuli.
Levels of plasma CORT were measured at 0, 30, and 60 min following exposure to LiCl
(127.2 mg/kg; i.p.) (a), Coc (15 mg/kg; i.p.) (a), RES (30 min) (b), or 5-HT (40 µg; 4V)
(c). All of these stimuli significantly increased plasma CORT 30 min post-exposure when
compared to their relative controls (a-c). CORT levels at 30 min post stimuli-exposure
were compared for all experimental groups, LiCl, Coc, and RES groups were all similar
to each other but were significantly lower than the CORT levels of 5-HT-treated group
(d). All data expressed as mean ± SEM (n = 4-6 per treatment group). Panels (a-c) were
analyzed using a two-way ANOVA followed by Bonferroni post-hoc analysis (*P<0.05;
**P<0.01; ****P<0.0001; #P=0.0557). Panel (d) was analyzed using a one-way ANOVA
followed by Tukey post-hoc analysis (P<0.0001).

82

83

Figure 3.2. Pharmacological blockade of hindbrain 5-HT2C and 5-HT3 receptors
decrease c-Fos expression in NTS PPG neurons following LiCl and novel restraint.
Pre-treatment with hindbrain (4V) RS1 (40 µg) or OND (20 µg) was followed by LiCl
(127.2 mg/kg; i.p.) (a-c), Coc (15 mg/kg; i.p.) (d-f), or RES (30 min) (g-i). In the LiCltreated groups, the increase in NTS c-Fos expression (a) and the increase in colocalization between c-Fos and GLP-1 immunoreactive cells (b) were both reversed by
pre-treatment with either OND or RS1. Treatment with either 5-HTR antagonist reversed
the increase in NTS c-Fos expression induced by Coc (d), however, the co-localization
between c-Fos and GLP-1 immunoreactive cells was unaffected (e). The increase in
NTS c-Fos expression induced by RES was not significantly affected by pre-treatment
with OND or RS1 (g). Treatment with OND or RS1 caused an attenuation in colocalization between c-Fos and GLP-1 immunoreactive cells (h). Representative images
of co-localization between c-Fos (green) and GLP-1 (red) immunoreactivity for the main
treatment groups (c, f, i). All data expressed as mean ± SEM and were analyzed using a
two-way ANOVA (n = 3-6 per treatment group). Different letters are significantly different
from each other (p<0.05) according to Tukey post hoc analyses.
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Figure 3.3. Effect of pharmacological blockade of hindbrain 5-HT2C and 5-HT3
receptors on c-Fos expression in NTS PPG neurons following LiCl, cocaine, and
novel restraint. Zoomed-out images from Figure 1 to help visualize c-Fos expression
within an entire hemisphere of the NTS in each of the main treatment groups. Changes
in PPG and c-Fos colocalization in the NTS following treatment with LiCl (a), Coc (b), or
RES (c).
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Figure 3.4. Combined pre-treatment of OND and RS1 attenuates c-Fos expression
in NTS PPG neurons induced by novel restraint. Animals received a combo pretreatment (4V) of RS1 (40µg) and OND (25µg) followed RES (30min). The combo
treatment caused an attenuation in co-localization between c-Fos and GLP-1
immunoreactive cells (a). Representative images of co-localization between c-Fos
(green) and GLP-1 (red) immunoreactivity for the main treatment groups (b). All data
expressed as mean ± SEM and was analyzed using a one-way ANOVA. Means with
different letters are significantly different from each other (p<0.05) according to Tukey
post hoc analyses.
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Figure 3.5 (Table 1). Number and distribution of PPG and/or c-Fos immunopositive
neurons in the rat NTS following pre-treatment with either OND or RS1 and exposure to
either LiCl, Coc, or RES.
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Figure 3.6. Increased c-Fos expression in the CR in response to stimuli that
engage the central GLP-1 system is driven by the RMg. Representative sections of
the RPa, ROb, and RMg showing the presence of 5-HT neurons in each of the three CR
sub-nuclei (a). Exposure LiCl and RES caused a significant increase in c-Fos
immunoreactivity in the CR (Total CR), within the individual nuclei there was a significant
increase in the RMg, but not in the RPa or ROb (b-c). Treatment with Coc had no effect
on total c-Fos expression in any of the CR sub-nuclei (d). Total CR = RPa + ROb + RMg.
All values are expressed as MEAN +/- SEM (n = 3-6 per treatment group). Data were
analyzed using an unpaired t-test (p < 0.05).
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Figure 3.7. Systemic LiCl and novel restraint increase c-Fos expression in 5-HT
neurons in the RMg. LiCl (a-b) and RES (e-f) significantly increased co-localization
between 5-HT and c-Fos immunoreactive cells in the CR (Total CR). In both groups the
increase in co-colocalization was significant in the RMg but not in the ROb or RPa.
Treatment with Coc did not cause significant changes in 5-HT/c-Fos co-localization in
any of the CR sub-nuclei (c-d). Representative images of co-localization between c-Fos
(green) and 5-HT (red) immunoreactivity for the main treatment groups in each of the CR
sub-nuclei (b,d,f). Total CR = RPa + ROb + RMg. All values are expressed as MEAN +/SEM (n = 3-6 per treatment group). Data were analyzed using an unpaired t-test
(p<0.05).
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Figure 3.8. Effect of LiCl, cocaine, and novel restraint on c-Fos expression in 5-HT
neurons in the RMg. Zoomed-out images from Figure 3 to help visualize c-Fos
expression within an entire hemisphere of the NTS in each of the main treatment groups.
Changes in 5-HT and c-Fos colocalization in the caudal raphe and its subniclei following
treatment with LiCl (a), Coc (b), or RES (c). Total CR = RPa + ROb + RMg.
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Figure 3.9 (Table 2). Number and distribution of 5-HT and/or c-Fos immunopositive
neurons in the rat CR following exposure to either LiCl, Coc, or RES.
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Figure 3.10. Methods and controls for mono-trans-synaptic viral tracing from the
RMg to the NTS. Rats (n=18) received a cocktail injection containing an AAV1 Cre
anterograde tracer and cholera toxin B (CTB)-488 (50nl) into the RMg and a Credependent AAV1-FLEX-TD- Tomato (100nl /hemisphere) virus into the NTS (a). Three
weeks following the viral injections the animals were transcardially perfused, brains were
harvested, and tissue was processed for FISH/IHC analysis. The site of injection was
verified using anti-CTB antibody in the RMg (a, bottom left). The trans-synaptic
properties of the AAV1 Cre was confirmed via the presence of TD-Tomato-expressing
neurons in the NTS (a, bottom right). Validation for injection site specificity (b, top
panels), dependency on the presence of Cre for the expression of TD-Tomato (b, middle
panels), and lack of bleed-through of TD-Tomato into other channels (b, bottom panels).

95

Figure 3.11. Placements of AAV1-Cre injection sites in the RMg based on the atlas
of Paxinos and Watson 2005. Diagram illustrating representative injection sites for all 4
animals in which CTB immunoreactivity localized exclusively within the RMg. 4V = 4th
ventricle; RMg = Raphe Magnus.
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Figure 3.12. RMg neurons project mono-synaptically to PPG neurons in the NTS.
FISH/IHC was conducted on TD-Tom tagged NTS sections using an mRNA probe for
PPG neurons (green) and a 5-HT antibody (blue) (n = 4). Neurons showing PPG/TDTom co-localization were identified in the AP- level NTS (a), Obex-level NTS (b), and
Post-Obex NTS (c) sections. A representative obex-level NTS section at ×20 and x40
magnification is shown in (b), PPG are shown in green, TD-Tomato-expressing neurons
in red, and 5-HT fibers in blue. Subpanel b-1 shows an optical zoom of two neurons colocalizing PPG and TD-Tom. Representative frame of three-dimensional rotational video
showing PPG and TD-Tom co-expressing neurons in close opposition to 5-HT axons
Subpanel b-2 (video can be found in the supplement data). The video was obtained from
a z-stack collected from the mNTS at the level of the obex with the × 40 oil-immersion
objective and a 4-5 optical zoom. A total of 43% of PPG neurons co-localized with TDTom, at the level of the pre-obex there was a 50% co-localization while at the obex-level
there was a 37% co-localization (c).
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Figure 3.13. The NTS is densely innervated by 5-HT projections. IHC was conducted
on hindbrain NTS sections using a 5-HT antibody at three different rostral-caudal planes
of the NTS, AP-level (a), Obex-level (b), and Post-Obex (c). Representative images of
each rostral-caudal plane were taken at 10X (top) and 20X (bottom) magnifications.
Representative images (a-c) show expression of 5-HT fibers (green) among the three
rostral-caudal planes that were analyzed. 5-HT fibers were most densely aggregated in
the NTS in all three rostral-caudal planes.
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CHAPTER 4: General Discussion and Conclusion
The development of future pharmacotherapies for the treatment of metabolic disease, as
well as stress-related disorders, depends on a more holistic understanding of the neurotransmitters / -peptides that regulate our physiology and how these signals interact with
each other to maintain homeostasis. More specifically, understanding how feeding is
affected by the interaction between different neurosubstrates is essential to develop
pharmacotherapies with increased efficacy and reduced side effects. The data
presented in this dissertation provides evidence that the central 5-HT and GLP-1
systems interact within the hindbrain and that this interaction affects feeding behavior
and stress-mediated neuronal activity. My thesis work examined: [1] the directionality of
the 5-HT/GLP-1 interaction within the hindbrain of the rat, [2] two 5-HT receptors
involved in modulating central GLP-1 signaling to affect food intake, [3] the potential
source of 5-HT input to the GLP-1-producing PPG neurons, and [4] the role of 5-HT2C
and 5-HT3 receptors in mediating NTS PPG activity in response to acute stressors.
Collectively, the data gathered over the last five years broadens our understanding of
the central GLP-1 system and brings attention to the relevance of its interaction with the
serotonergic system. In this chapter, I summarize key findings, address unanswered
questions that arose as a consequence of these discoveries, discuss the current state of
the literature, and put forward future avenues of basic science and clinical research.
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Potential Bi-Directionality of the interaction between 5-HT and GLP-1
Data presented in Chapter 2 indicates that, within the rat hindbrain, the 5-HT/GLP-1
interaction is driven by 5-HT having a modulatory effect on the central GLP-1 system. To
date, the literature examining the interaction between these two systems is fairly split
with evidence supporting both 5-HT modulating the GLP-1 system, as well as GLP-1
modulating the 5-HT system. As such, it is important to place the findings of this
dissertation into the bigger context of the current scientific literature. The first study to
report an interaction between the 5-HT and GLP-1 systems was published in 2002 with
the objective of highlighting the involvement of different neurotransmitter systems in the
biological effects of GLP-1 (Owji et al, 2002). Since then, many other groups have
examined the 5-HT/GLP-1 interaction in the CNS, as well as the periphery (e.g. colon,
ilium, duodenum, and plasma), and have employed various animal models (e.g. mice,
rats, pigs, humans, and chickens) and techniques, as discussed below [for a summary of
all of the studies see table 4.1]

GLP-1 modulates the 5-HT system. In 2002, Owji et al. reported that central
administration (3V) of GLP-1 or Ex-4 reduces hypothalamic levels of glutamate, GABA,
and 5-HT in rats (Owji et al, 2002). In accordance with this finding, other groups have
also reported the ability of GLP-1R agonists to reduce 5-HT levels in the periphery. One
study showed that systemic treatment (i.p.) with Ex-4 reduces 5-HT concentration in the
colon and increases expression of the serotonin transporter (SERT) in vivo (Yang et al,
2014). The increase in SERT expression following treatment with Ex-4 has also been
observed in vitro using intestinal epithelial cell culture where it was shown to be
100

achieved via the AC/PKA signaling pathway (Cui et al, 2020b). In contrast with these
findings, however, other groups have reported that GLP-1R agonists increase 5-HT
activity. Brunetti et al., using in vitro hypothalamic synaptosomes showed that bath
application of Ex-4 increases 5-HT release (Brunetti et al, 2008). One of the more recent
and elaborate studies looking at the 5-HT/GLP-1 interaction was conducted by a team at
the University of Gothenburg. This study used whole cell electrophysiology recordings to
show that bath application of Ex-4 increased electrical activity of dorsal Raphe (DR) 5HT neurons (Anderberg et al, 2017). The ability of GLP-1 to increase 5-HT activity has
also been reported in the periphery, where the GLP-1R agonist, liraglutide, was shown
to stimulate 5-HT release from ex vivo intestinal duodenum and colon mice samples
(Lund et al, 2018). Although there are numerous reports that support GLP-1 having a
modulatory effect on the 5-HT system, whether this effect ultimately functions to
stimulate or inhibit the 5-HT system is still heavily contested.

5-HT modulates the GLP-1 system. There is a higher consensus among the studies that
report a modulatory effect of 5-HT on the GLP-1 system. In fact, all but one of these
studies indicate that 5-HT stimulates activity of the GLP-1 system. For starters,
exogenous administration of 5-HT4R and 5-HT1BR agonists increase plasma levels of
GLP-1 in mice and humans (Aoki et al, 2013; Nonogaki et al, 2015a, b). Meanwhile, bath
application of 5-HT increases GLP-1 release from pig ileum sections (Ripken et al,
2016). From a behavioral standpoint, blockade of 5-HT2C and 5-HT3 receptors, via
genetic or pharmacological manipulations, hinder GLP-1’s effect on food intake and
nociception in mice respectively (Asarian, 2009; Aykan et al, 2019; Nonogaki et al,
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2011). Within the CNS, a study in 2017 looking at the 5-HT/GLP-1 interaction in the
hindbrain showed that a large percent of NTS PPG neurons (50-80%) are innervated by
serotonergic projections in mice (Holt et al, 2017). Data presented in Chapter 2 further
supports 5-HT’s modulatory effect on the GLP-1 system. First, the anorectic feeding
behavior induced by hindbrain (4V) administration of 5-HT was shown to be mediated
via central GLP-1R signaling. Second, the presence of mRNA transcripts for the 5-HT2C
and 5-HT3 receptors were identified on NTS PPG neurons. Third, hindbrain
pharmacological activation of either of these two 5-HT receptors was sufficient to reduce
food intake and this effect was also dependent on GLP-1R signaling. These data support
the notion that, at least within the hindbrain, the relationship between 5-HT and GLP-1
favors 5-HT having a modulatory effect on the central GLP-1 system.

The one study that shows 5-HT having an inhibitory effect on GLP-1 was published by a
group from Hokkaido University in Japan (Okumura et al, 2020). In this study,
intragastric administration of the 5-HT4R agonist, tegaserod, reduced the dietary lipidinduced increase of plasma GLP-1 in mice. However, this effect seemed to depend on
route of administration and feeding conditions, given that intraperitoneal or intragastric
administration of tegaserod had no effect on plasma GLP-1 levels in fasted mice
(Okumura et al, 2020). Further, a separate study reported that intraperitoneal
administration with a different 5-HT4R agonist, mosapride citrate, causes an increase in
plasma levels of GLP-1 in mice, an effect that was independent of feeding (Nonogaki et
al, 2015a). It’s possible that this discrepancy is attributed to the binding affinity or
receptor specificity of the different 5-HT4R agonists employed in these different studies.
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Both pharmacological agents are considered non-selective 5-HT4R agonists. Tegaserod
is a partial 5-HT4R agonist, in addition to its affinity for 5-HT4Rs, it has affinity for 5HT1A, 5-HT1B, 5-HT1D, 5-HT2A, and 5-HT2B. Meanwhile, mosapride citrate has affinity
for 5-HT3Rs in addition to 5-HT4Rs (De Maeyer et al, 2008; Tack et al, 2012).

The diversity among the studies that have reported an interaction between 5-HT and
GLP-1 provides convincing evidence of a true interaction. However, this diversity also
contributes to the conflicting results between studies. These seemingly clashing
discoveries may well be the result of a more complex interaction. This idea is supported
by Holt et al., who—using extracellular recording—found that bath application of 5-HT
causes divergent changes in electrical activity of NTS PPG neurons in mice with 44% of
the recorded cells showing reduced firing, 31% increased firing, and 25% showing no
change (Holt et al, 2017). In its current state, the literature seems to indicate that the
interaction between the 5-HT and GLP-1 systems is likely bidirectional and dependent
on multiple factors including, but not limited to, source of modulator, animal model, sex
differences, and experimental design. Regardless of these differences, the presence of
an interaction is well accepted within the literature and the intricacies that underlie it are
beginning to be unraveled.

The role sex plays in the 5-HT/GLP-1 interaction is particularly complicated because of
the lack of data available for each individual system. To this day females are
underrepresented in pre-clinical studies and, unfortunately, the GLP-1 field is no
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exception. Few studies have focused on assessing differences in GLP-1 between males
and females and some of these findings are conflicting. Chan et al., found no difference
is fasting levels of GLP-1 among nonobese Asian men and women (Chan et al, 2018).
According to other studies, however, normoglycemic women are characterized with
increased serum GLP-1 concentrations following an OGTT when compared to men,
even after adjusting for BMI (Tramunt et al, 2020). Although the role sex plays in the
regulation of the GLP-1 system is still unclear, the ability of estradiol to regulate both αand L cells to increase GLP-1 secretion (Handgraaf et al, 2018) supports the presence
of potential sex difference. In support of this, a study in 2016 showed that female rats
displayed an increased sensitivity to the food reward effects of central GLP-1 receptor
activation. Additionally, the study demonstrated that central estrogen receptor-α (ERα)
signaling was necessary for the effects of GLP-1 on food-reward behavior in both sexes
(Richard et al, 2016). In the presence of homeostatic disturbances and pathology, there
also seems to be some degree of sex differences. When compared with individuals with
normal glucose tolerance, women with prediabetes or type 2 diabetes had 25% lower
GLP-1 response to an oral glucose tolerance test (OGTT), this was not observed in men
(Færch et al, 2015). Further, chronic systemic treatment with liraglutide among juvenile
rats prevented body weight gain in males, but not females (Liberini et al, 2019). The
literature supports the presence of sex differences with regards to the GLP-1 system,
however, additional studies are needed to delineate this difference and explore its effect
under pathological conditions.
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Role of 5-HTRs on the interaction between 5-HT and GLP-1
The serotonergic receptor system is large and complex, it’s composed of seven families
that comprise fourteen different functional receptor sub-types (Barnes et al, 1999). Of
the 5-HT receptors, seven have been confirmed to be present in the NTS: 5-HT1A, 5HT1B, 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, and 5-HT7 (Abramowski et al, 1995; Doucet et
al, 2000; Edwards and Paton, 1999; Gustafson et al, 1996; Laporte et al, 1992; Manaker
and Verderame, 1990; Pazos et al, 1985; Pompeiano et al, 1994). The work presented
in Chapters 2 and 3 focus on the role that the 5-HT2C and 5-HT3 receptors play in
modulating central GLP-1 signaling in the context of feeding (Chapter 2) and assess
their ability to mediate NTS PPG activity in response to acute stressful stimuli (Chapter
3). These two receptors have also been implicated in the 5-HT/GLP-1 interaction by
other groups, as have the 5-HT1B, 5-HT2A, and 5-HT4 receptors. The following
paragraphs will discuss the literature on each of these receptors.

The anorectic effect induced by systemic activation of the 5-HT2C and the 5-HT3
receptors is well-established in the literature (Castro et al, 2002; Dunlop et al, 2005;
Higgins et al, 2015; Higgins et al, 2016; Li et al, 2015; Martin et al, 1998; MazzolaPomietto et al, 1995; Redman et al, 2010; Thomsen et al, 2008; Van Der Hoek and
Cooper, 1994). Recently, both receptors have been linked to the GLP-1 system with
three different reports demonstrating that 5-HT signaling via these receptors is
necessary for some GLP-1-mediated functions (Asarian, 2009; Aykan et al, 2019;
Nonogaki et al, 2011), these will be discussed in detail in a later section. Data presented
in this document contributes to this literature. Discoveries in Chapter 2 revealed the
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presence of mRNA transcripts for both of these receptors on NTS PPG neurons in the
rat, with over half of the NTS PPG neurons (55%) expressing transcripts for both
receptors. The expression of these 5-HT receptors was heterogeneous with no obvious
pattern of expression between hemispheres or along the rostral/caudal plane. Further,
Chapter 3 showed that the 5-HT2C and 5-HT3 receptors mediate NTS PPG activity, as
read-out by c-Fos, in response to different acute stressors. Data presented in this
dissertation combined with the scientific literature provide significant evidence that both
the 5-HT2C and the 5-HT3 receptors contribute to the modulatory effect of 5-HT on the
GLP-1 system. However, the extent of their effect and the behavioral circumstances
under which their contribution is relevant are still being explored.

The 5-HT4 receptor is excitatory in nature, it’s a G protein-coupled receptor paired to a
Gs protein, and it’s expressed in the periphery as well as CNS (Barnes et al, 1999;
Edwards et al, 1999; Hoffman et al, 2012; Mader et al, 2006; Varnäs et al, 2003; Vilaró
et al, 2002). In mice, systemic administration with a 5-HT4R agonist (mosapride citrate)
significantly increased plasma levels of active GLP-1, an effect that was magnified when
combined with a selective dipeptidyl peptidase-4 (DPP-4) inhibitor (Nonogaki et al,
2015a). As a reminder, DPP-4 is the enzyme responsible for the degradation of GLP-1.
In a human study, non-diabetic men receiving an oral administration of the same 5HT4R agonist (mosapride citrate, 20 mg) showed increased plasma levels of active and
total GLP-1 when compared to the control group, this was achieved in the absence of a
DPP-4 inhibitor (Aoki et al, 2013). Combined, these studies suggest that the 5-HT4
receptor helps mediate 5-HT’s stimulatory effect on the GLP-1 system. This effect is
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likely due to an increase in GLP-1 secretion, rather than inhibiting DPP-4 activity.
However, this idea is challenged by a recent study showing that intragastric
administration of a different 5-HT4R agonist (tegaserod) reduces dietary lipid-induced
increase in plasma GLP-1 in mice (Okumura et al, 2020). Further, Lund et al. showed
that GLP-1 engages downstream 5-HT4R signaling to produce L-cell differentiation in
mice, indicating that 5-HT4 receptors may be involved in a bidirectional manner (Lund et
al, 2020). Overall, there is evidence supporting the 5-HT4 receptor playing a role in the
interaction between 5-HT and GLP-1. Additional studies are needed to understand the
specifics of its role and how its effects are influenced by route of administration, affinity
of pharmacological agonists, and animal model.

The 5-TH1B receptor is the only inhibitory 5-HT receptor that has been implicated in the
5-HT’s effect on the GLP-1 system. Following four days of treatment with a DPP-4
inhibitor, systemic administration of a selective 5-HT1B receptor agonist (CP94253)
increased plasma levels of GLP-1 in mice (Nonogaki et al, 2015b). While this suggests
that 5-HT1B receptors might contribute to 5-HT’s ability to modulate the GLP-1 system,
its dependence on pre-treatment with a DPP-4 inhibitor indicates that this effect is mild
or a consequence of enhancing the inhibitory effect of the DPP-4 inhibitor. As it stands
the evidence for the 5-HT1B receptor playing a role in the 5-HT/GLP-1 interaction is
lacking.
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Thus far, all the studies presented in this section have addressed 5-HT’s effect on the
GLP-1 system. However, there are two studies that looked at the effects of GLP-1 on 5HTR expression. A study in 2017 reported that central administration (LV) of Ex-4 or
GLP-1 eliminated the increase in mRNA levels of hypothalamic 5-HT1A, 5-HT2A, 5HT2C, and 5-HT3A receptors induced by restricted feeding (Anderberg et al, 2017).
Likewise, intraperitoneal injection of liraglutide (GLP-1R agonist) decreased the
expression of hypothalamic 5-HT2A receptors, but not 5-HT2C receptors, when
compared with saline controls (Nonogaki et al, 2018). These studies illustrate the ability
of GLP-1 to downregulate mRNA expression of some hypothalamic 5-HT receptors in
mice. Unfortunately, neither study looked at whether the effect on mRNA expression led
to changes in protein expression levels of 5-HTRs. The potential behavioral effects of
these changes will be discussed in the next section.

Of the different 5-HT receptor subtypes expressed in the NTS, the 5-HT7 is the only
receptor that has not been explored within the context of the 5-HT/GLP-1 interaction.
The 5-HT7 is an excitatory G protein-coupled receptor and has been associated with
mood regulation, circadian rhythm, cognition, pain, and epilepsy [for a review on 5-HT7
function and therapeutic literature see (Nikiforuk, 2015) ]. Despite its wide range of
biological functions, it remains unclear whether any therapeutic efficacy can be achieved
via pharmacological manipulation of this receptor.
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5-HT modulates GLP-1-mediated effects
The interaction between the 5-HT and the GLP-1 system is a fairly new area of research,
which is why most of the studies have focused on understanding this interaction at a
molecular level and less so on its physiological and behavioral consequences.
Nonetheless, there have been a few studies suggesting that the interaction between
these systems influence some of the GLP-1-mediated effects, including: feeding
behavior, glucose tolerance, stress response, and nociception. This section will review
the available literature on how 5-HT contributes to GLP-1-mediated effects.

The role of 5-HT on GLP-1’s effect on feeding behavior. The relationship between 5-HT
and GLP-1 in the realm of feeding appears to be two-fold. First, the anorectic effect of
treatment with GLP-1 relies on intact 5-HTR expression. Evidence for this comes from
two separate studies in which the anorectic effect of systemic GLP-1 was blunted in
mice with a genetic deletion for the 5-HT2C receptor (Asarian, 2009; Nonogaki et al,
2011). Second, the GLP-1 system is activated to mediate 5-HT’s anorectic effect. This is
illustrated in Chapter 2 where the anorectic effect of treatment (4V) with 5-HT, Lor (5HT2CR agonist), and SR5 (5-HT3R agonist) were blocked upon pre-treatment with the
GLP-1R antagonist, Ex-9. These results suggest that central 5-HT involves signaling via
the 5-HT2C and 5-HT3 receptors and relies on GLP1-R signaling to influence feeding
behavior in rats. Though the directionality remains uncertain, findings presented in this
dissertation combined with the available literature demonstrate that the anorectic effect
induced by the 5-HT and the GLP-1 system are interconnected. It is possible that in mice
GLP-1’s effect on feeding is mediated via a 5-HTR-mechanism. While in the rat, 5-HT’s
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anorectic effect is reliant on GLP-1R signaling. However, there is not enough data to rule
out that both cases are true in both species, pivoting back to the bidirectionally
hypothesis. A question that remains to be answered is whether the effects on feeding
behavior driven by the 5-HT/GLP-1 interaction are acute or whether it persists
chronically. If the latter were true, it would of interest to examine the effect of this
interaction on changes in body weight. For example, if chronic hindbrain (4V)
administration of 5-HT resulted in reduced body weight in rats, would this effect be
reversed upon central GLP-1R blockade? Although changes in food intake and body
weight are often thought about in tandem they are not always correlated, and this
difference has a considerable impact on therapeutic potential.

The feeding effects of the interaction between 5-HT and GLP-1 may be contributing to
the metabolic syndrome observed in patients who are being treated with antipsychotics.
While the exact mechanism of actions remains elusive, atypical antipsychotics—such as
Olanzapine—have a lower affinity for the dopaminergic receptors and an added affinity
for serotoninergic receptors (Seeman, 2002). The relative high affinity for 5HT2A
receptors has been often credited for the therapeutic actions of olanzapine, however, it
also has a high affinity for the 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7 receptors (Itoh,
2019). In fact, the hyperphagia, weight gain, and potentially hyperglycemic effects of
olanzapine have been linked to its antagonistic actions on the 5-HT2C receptor (Lord et
al, 2017). Lord et al, showed that treatment with a 5-HTR2CR agonist (lorcaserin)
suppressed olanzapine-induced hyperphagia, weight gain, and improved glucose
tolerance in olanzapine-fed mice (Lord et al, 2017). Likewise, a plethora of recent
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studies suggest treatment with GLP-1R agonists as an effective treatment for
antipsychotic-associated weight gain and hyperglycemia (Babic et al, 2018;
Dayabandara et al, 2017; Ebdrup et al, 2012; Lykkegaard et al, 2008; Medak et al, 2020;
Siskind et al, 2019). Whether the ability of GLP-1R and 5-HT2CR agonists to ameliorate
olanzapine-mediated metabolic syndrome are linked remains to be determined.

The role of 5-HT on GLP-1’s effect on glucose tolerance. Glucoregulation is one of the
first discovered functions of GLP-1 and it’s achieved by increasing insulin secretion from
pancreatic β-cells (Drucker and Nauck, 2006; Drucker et al, 1987). Two studies indicate
that 5-HT receptors improve glucose tolerance in mice when combine with a DPP-4
inhibitor. In these studies, mice were treated with DPP-4 inhibitor (alogliptin) for four
days prior to testing. On the day of testing, the animals were fasted for five hours before
receiving a systemic administration with either saline or a pharmacological agonist for
the 5-HT4 or 5-HT1B receptors. Animals in the experimental group showed significantly
lower levels blood glucose in response to a systemic injection of D-glucose when
compared to the saline-treated groups (Nonogaki et al, 2015a, b). The 5-HT4R agonist
(mosapride citrate) increased glucose tolerance even in the absence of alogliptin
treatment, this data was not provided in the 5-HT1b study. While it is still speculative, it’s
possible that these receptors— the 5-HT4 and 5-HT1B—interact with the GLP-1 system
to influence glucose metabolism. The idea that the 5-HT system plays a role in GLP-1mediated glucoregulation, is supported by studies showing that serotonin stimulates beta
cell proliferation and that 5-HT receptors have been implicated in the glucose-mediate
insulin release in humans and mice (Bennet et al, 2016; Moon et al, 2020). An avenue
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for future pre-clinical research would be to assess whether the insulin-enhancing effects
of GLP-1R-based therapeutics are affected by pharmacological manipulation of 5-HT1B
or 5-HT4 receptors.

The role of 5-HT on GLP-1’s effect on stress. There is almost no data on the effects the
5-HT/GLP-1 interaction has on stress-mediated behaviors. This is part of what motivated
the work presented in this dissertation as I was interested in better understanding how
feeding and stress mechanism interact and how that interaction affects stress. The data
discussed in Chapters 2 and 3 are my contribution to better understanding how the 5HT/GLP-1 interaction influences stress.

In two back-to-back studies in 1999 Rinaman showed that the interoceptive stressor LiCl
activates NTS PPG neurons that project to the PVN and that the mechanism underlying
LiCl’s anorectic effect involves endogenous GLP-1 neural pathways (Rinaman, 1999a,
b). Given that LiCl requires the engagement of the central GLP-1 system to achieve its
anorectic effect and that 5-HT is a modulator of the GLP-1 system, one of the earliest
questions I proposed was whether hindbrain 5-HTRs played a role in mediating LiCl’s
anorectic effect. This question was addressed in Chapter 2, where I showed that
pharmacological blockade of hindbrain 5-HT3 receptors abolishes the acute anorectic
effect of LiCl. This provided the first piece of evidence that indirectly linked the 5HT/GLP1 interaction to stress-induced hypophagia. A direct effect would have required the effect
of ondansetron on LiCl-induced anorexia to be abolish by central blockade of GLP-1Rs,
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however, this was not assessed at the time. Data in Chapter 3 addressed the question of
whether 5-HT receptors in the hindbrain mediate NTS PPG activity in response to acute
stressors. Results revealed that both 5-HT2C and 5-HT3 receptors are involved in
mediating the increased NTS PPG activity that results from exposure to LiCl and novel
restraint, but not in response to an acute dose of cocaine. These data provide evidence
that, within the hindbrain, the interaction between the 5-HT and GLP-1 systems directly
influences GLP-1-mediated neuronal activity in the context of stress. What was not
address in the work presented in this document and what future studies should address
is whether the anxiogenic—and other mood-related— effects of GLP-1/GLP-1R agonists
are influenced by 5-HTR signaling.

The role of 5-HT on GLP-1’s effect on nociception. Recent reports indicate that GLP- 1based therapies have anti-inflammatory effects on various organs—including the liver,
kidney, lung, testis, skin, vascular system, and brain. These effects are mediated
through a reduced production of inflammatory cytokines, tissue-specific infiltration of
immune cells, and activation of the PKA/CREB pathway (Lee et al, 2016; Que et al,
2019). In addition to its anti-inflammatory properties, intrathecal administration of GLP1R agonists decrease hypersensitivity induced by formalin, peripheral nerve injury, and
bone cancer (Gong et al, 2014) and reduce mechanical allodynia caused by spinal nerve
ligation (Cui et al, 2020a). A 2019 study showed that systemic administration of the 5HT3R antagonist, ondansetron, significantly decreased the antinociceptive actions of
GLP-1 (i.p.) on the hot plate test (Aykan et al, 2019). However, the molecular
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mechanisms underlying this effect and whether central GLP-1 plays a role in modulating
nociception are unknown.

Potential Mechanism Underlying 5-HT’s modulatory effect on the central GLP-1
system
Although many studies report 5-HT having a modulatory effect over the GLP-1 system—
prior to the work presented in dissertation—only one study had examined this effect in
the hindbrain (Holt et al, 2017). Much work remains to be done to fully understand the
intricacies of the cellular mechanisms underlying this interaction and confirm the source
of 5-HT input that functions as an endogenous driver of central GLP-1 system. The work
presented in this dissertation helped shed some light into these questions.

Serotonin could engage the central GLP-1 system either directly or indirectly. Data
presented in this document supports a potential direct mechanism of action. First, NTS
PPG neurons express mRNA transcript for both the 5-HT2C and the 5-HT3 receptors
(Chapter 2). Second, selective hindbrain blockade of these 5-HT receptors abolishes the
increase in c-Fos expression observed in NTS PPG neurons following LiCl (Chapter 3).
Taken together, these results suggest that 5-HT could be modulating the central GLP-1
system through a direct activation of the 5-HT2C and 5-HT3 receptors expressed on
NTS PPG neurons. However, experiments conducted in this body of work did not rule
out the possibility of an indirect mechanism. The blockade of 5-HT2 and 5-HT3 receptors
conducted in the stress-exposure experiments in Chapter 3 was achieved via 4V
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administration of pharmacological antagonist. As such, the blockade of 5-HTRs was not
specific to the NTS, nor to PPG neurons. This leaves room for the possibility that 5-HT
could be modulating PPG neurons indirectly by engaging a separate population of
hindbrain neurons. In this scenario, the population of unidentified neurons would be the
intermediary step between incoming 5-HT input and the engagement of NTS PPG
neurons. Supposing this population of neurons were located within the NTS they could
be CCK or noradrenergic neurons, given that both engage the GLP-1 system (Hisadome
et al, 2011; Maniscalco et al, 2017; Rinaman, 2011). Future studies are required to fully
characterize the specific cell types that express 5-HTRs within the NTS and to the better
understand how neurons within the NTS interact.

The molecular signaling cascades through which GLP-1 mediates its biological functions
are not well understood. In the realm of feeding, the anorectic effects of Ex-4 have been
associated with increased PKA activity (Hayes et al, 2011). This upregulation in PKA is
accompanied

by

increased

phosphorylation

of

p44/42-MAPK

and

decreased

phosphorylation of AMPK and Akt (Hayes et al, 2011; Rupprecht et al, 2013a). Changes
in PKA activity have recently also been implicated in the 5-HT/GLP-1 interaction. A 2020
study in which bath application of Ex-4 led to increased SERT expression in vitro also
reported increased PKA activity in the Ex-4-treated cells. This effect was reversed by
pretreatment with an adenyl cyclase inhibitor, suggesting that ability of GLP-1Rs to
influence SERT expression is achieved via the AC/PKA signaling pathway (Cui et al,
2020b). The downstream effects of PKA activation or how those effects result in
physiological changes is still unknown.
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Given the diversity of biological functions linked to the 5-HT and GLP-1 systems, it is
unlikely that one specific pathway underlies the breadth of their interaction. What is more
likely, is that there are multiple target nuclei and different signaling pathways that are
engaged downstream. The specific nuclei that are targeted by NTS PPG neurons are
likely to depend on the context and behavior being studied. For example, the anorectic
and weight loss effects of GLP-1 and its analogs involve GLP-1Rs in the PBN, NTS/AP,
lateral septum, lateral dorsal tegmental nucleus (LDTg), and arcuate nucleus of the
hypothalamus (Alhadeff et al, 2014; Alhadeff et al, 2017; Hayes et al, 2011; Reiner et al,
2017; Secher et al, 2014; Terrill et al, 2019). In the case of motivated behaviors, GLP1Rs expressed in the VTA and NAc are involved (Alhadeff et al, 2012; Hernandez et al,
2018; Schmidt et al, 2016). Whereas GLP1Rs in the amygdala and PVN are some of the
nuclei targeted in GLP-1’s effect on stress (Kinzig et al, 2003). What has become clear is
that the relationship between external stimuli and the resulting activation of GLP-1Rs
within specific nuclei is not clearly delineated; it is not a one-to-one relationship. Whether
the downstream activation of different GLP-1R-expressing nuclei depend on different
signaling cascades or on sub-populations of PPG neurons that respond to specific
stimuli is unknown.

Chapter 3 explored the caudal Raphe as a potential source of 5-HT input driving the 5HT/GLP-1 interaction. Data from this chapter showed that of the three sub-nuclei that
form the caudal Raphe, the RMg was the only region that showed an increase in c-Fos
expression of 5-HT neurons in response to acute stressors that engage NTS PPG
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neurons (i.e. LiCl and novel restraint). Another major finding from this chapter was the
presence of mono-synaptic projections from the RMg into NTS PPG neurons and the
proximity of some of these NTS PPG neurons to 5-HT axons. Together, this suggests
that the caudal Raphe, specifically the RMg, is a likely source of 5-HT input into NTS
PPG neurons—at least in the context of acute stressors. However, additional
experiments are needed to confirm that RMg axonal projections that innervate NTS PPG
neurons are serotonergic in nature. A potential way to address this would be to have the
AAV1.Cre trans-synaptic tracer that was delivered into the RMg be expressed under a 5HT promotor. This added specificity would allow only 5-HT-expressing neurons in the
RMg to become infected and transmit Cre-recombinase onto downstream neurons. In
addition to confirming the presence of 5-HT mono-synaptic input from the RMg to NTS
PPG neurons, testing the functional role of this synaptic connection is paramount.
Specifically, determining the role of 5-HT RMg-to-NTS input in mediating PPG activity
under stress and non-stress conditions and its effect on GLP-1-mediated behaviors. A
way to answer these questions would be to ablate 5-HT input from the RMg to the NTS
via optogenetic or chemogenetic manipulations. Comparing c-Fos expression of NTS
PPG in animals with ablated and intact RMg-5-HT under non-stressed conditions would
give insight into the role RMg-5-HT plays in modulating endogenous NTS PPG activity.
Exposure to different stressors would demonstrate how this circuit is affected by stress
and whether it is preferentially engaged by a specific type of stress. Examining how the
inhibition or activation of this circuit affects stress-induced hypophagia and anxiety-like
behaviors would be the final piece in translating how the hindbrain 5-HT-to-GLP-1 circuit
affects GLP-1-mediated behaviors. To test dependence of these behaviors on the
central GLP-1 signaling, central or nuclei-specific activation of GLP-1Rs can be used to
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try and reverse the effects induced by ablation of RMg 5-HT signaling. A point worth
noting is that while a lot of the genetic tools needed to conduct these experiments are
available in mice, they are not commercially available or not easily achieved in rats.

While the work presented in this dissertation has focused on 5-HT modulating the central
GLP-1 system, about half of the 5-HT/GLP-1 literature indicates that under some
circumstances the GLP-1 system regulates serotonergic activity. Supporting this is a
study in 2017 which showed that NTS PPG neurons innervate the dorsal raphe (DR) and
that activation of DR GLP-1Rs is sufficient to increase electrical activity of 5-HT neurons
and decrease food intake and body weight in mice (Anderberg et al, 2017). Presently,
the most likely scenario would be the presence of a bidirectional interaction between the
5-HT and GLP-1 systems. Whether this bidirectionality varies by species, by stimuli, by
site of action, or by all of these remains to be determined.

The effect of GLP-1 on stress-induced hypophagia versus ad libitum feeding
behavior
The effect of GLP-1 on feeding behavior has traditionally been attributed to satiation,
however, the increasing literature linking this hormonal system to different stress centers
has started to question this view. Studies looking at stress-induced hypophagia have
suggested that NTS PPG neurons are not essential for the long-term regulation of food
intake but are instead required for the anorectic effects that result from exposure to
stressful stimuli (Borner et al, 2018; Grill et al, 2004). It is now being debated whether
118

the anorectic effects of GLP-1 might be driven by aversive pathways, such as those
associated with nausea and gastric discomfort (Kanoski et al, 2012; Müller et al, 2019).

Activation of NTS PPG neurons is sufficient to suppress feeding in mice and rats
(Gaykema et al, 2017; Jessen et al, 2017; Kanoski et al, 2016; Liu et al, 2017; Sandoval
and D'Alessio, 2015; Shi et al, 2017). However, exogenous activation of these neurons
can lead to activity levels that surpass physiological limitations and, thus, may not
resemble the effects of endogenous activity. For example, excitatory DREADDS can
activate ~98% of PPG neurons (Gaykema et al, 2017) whereas only 50-70% are
activated by stressors and <50% by a large meal (Holt et al, 2019; Leon et al, 2021). A
recent study employing DREADDS and a mouse line expressing Cre-recombinase to
target NTS PPG neurons addressed this issue by assessing the physiological role of
endogenous GLP-1 in ad libitum vs stress-induced feeding conditions (Holt et al, 2019).
While pharmacogenetic activation of NTS PPG neurons using excitatory DREADDs
reduced food intake acutely (1-4h), this effect was not sustained following daily
activation of these neurons (Holt et al, 2019; Liu et al, 2017). Meanwhile,
pharmacogenetic inhibition of NTS PPG neurons had no effect on ad libitum feeding but
it did prevent the anorectic effect induced by acute novel restraint stress. Additionally, no
effect on ad libitum feeding nor body weight (measured every 2-3 days for over 2
months) was observed following chronic ablation of NTS PPG neurons. The authors
concluded that the activation of PPG neurons is sufficient to reduce food intake but is not
required to regulate ad libitum feeding emphasizing that “sufficiency does not prove
necessity” (Holt et al, 2019).
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Empirical evidence suggests that the role of GLP-1 in ad libitum feeding might vary by
species. Global and central knockdown of GLP-1 has shown limited effect on food intake
and body weight in mice (Holt et al, 2019; Scrocchi et al, 2000; Sisley et al, 2014). In
rats, however, reports indicate that endogenous GLP-1 does play a role in the long-term
regulation of normal feeding (Barrera et al, 2011a; Jessen et al, 2017; Kanoski et al,
2016). A 2011 study used pharmacological and viral-mediated genetic manipulations to
model chronic loss of function of the CNS GLP-1 system in rats. Hyperphagia and
increased fat accumulation was observed in both models, rats that received an shRNA
to knockdown NTS PPG expression and rats that received chronic Ex-9 (LV) (Barrera et
al, 2011a). Given the limited literature available, additional studies are needed to confirm
whether GLP-1’s effect on ad libitum feeding varies by specifies and if so, which model
best mimics the human condition. Further, if GLP-1’s effect on feeding is ultimately
driven by stress-related mechanisms what does this mean for the treatment of illnesses
like bulimia nervosa (BN) and binge eating disorder (BED). There is some promising
evidence that GLP-1R agonists could be used to treat for BN and BED (Da Porto et al,
2020; McElroy et al, 2018). How GLP-1-based therapies would affect BN/BED patients
with co-existing metabolic or psychiatric co-morbidities remains to be determined.

Effects of chronic treatment with GLP-1-based pharmacotherapies on the 5-HT
system and its interaction with the HPA
There are currently six FDA-approved GLP-1R agonists on the market and over 400 ongoing clinical trials (source: clinicaltrials.gov), many of which aim to identify novel
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therapeutic potential for GLP-1-based drugs. Despite the increasing enthusiasm there
are relevant basic science questions that should be addressed along-side—if not prior
to—the development of additional GLP-1-based drugs. One of these questions is, how
would chronic treatment with GLP-1-based therapies alter the 5-HT system and its
interaction with the HPA axis? The significant co-morbidity between metabolic and
stress-related disorders and the reliance on selective serotonin reuptake inhibitors
(SSRIs) to treat many psychiatric disorders make this a heavily relevant question that
remains to be addressed by the scientific community. Nonetheless, this section will
present literature that gives insight into what those effects might be.

The 5-HT system, stress, and the HPA: Under most conditions, acute stress increases
5-HT synthesis [for review see (Chaouloff et al, 1999)], which in turn engages the HPA
axis and leads to increased levels of stress hormones (Fuller and Snoddy, 1980; Heisler
et al, 2007; Silverstone et al, 1994). The presence of chronic stress leads to a host of
physiological changes including the dysregulation of HPA activity, which is characterized
by increased baseline cortisol levels and blunted ACTH in response to stress exposure
(Herman et al, 2016; Karin et al, 2020; Stephens and Wand, 2012). Chronic stress
causes a depletion of 5-HT through decreased 5-HT synthesis and increased 5-HT
uptake (Höglund et al, 2019; Miura et al, 2008; Tafet et al, 2001a; Tafet et al, 2001b).
Given its role in stress and mood regulation, during the twentieth century the 5-HT
system became a prime target for the treatment of stress- and mood-related disorders.
Presently, SSRIs are some of the most successful pharmacological therapies to treat
disorders that induce chronic hypersensitivity of the HPA axis. These 5-HT-based
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therapeutics function to increase 5-HT content and interfere with the dysregulation of the
HPA axis at different levels. For example, chronic treatment with SSRIs decreases
baseline cortisol levels in patients with major depressive disorder (Ruhé et al, 2015).
However, the mechanism of action of SSRIs seems to differ by mood disorder. The
therapeutic effect of SSRIs in treating depression and panic disorder is linked to
increased 5-HT at the synapse, while its effect on obsessive compulsive disorder (OCD)
is thought to be mediated via adaptations of post-synaptic receptors [for reviews on the
mechanism of action of SSRI view (Anderson, 2004; Nutt et al, 1999; Stahl, 1998)].
Overall, increasing 5-HT levels has been a successful therapy to treat mood- and stressrelated disorders though its effects are achieved via complex pre- and post-synaptic
adaptations of various 5-HTRs that are not fully understood.

GLP-1-mediated changes to the 5-HT system: GLP-1 modulates the serotonergic
system, however, whether it serves to increase or decrease 5-HT is still unclear given
that there is evidence for both effects (Brunetti et al, 2008; Hasni Ebou et al, 2016; Lund
et al, 2018; Owji et al, 2002; Yang et al, 2014). Contradicting results have been found
even when using the same GLP-1R agonist (Ex-4), in the same animal model (rat), and
within the same site of action (the hypothalamus) (Brunetti et al, 2008; Owji et al, 2002).
All that can be said for sure at this point is that acute activation of the GLP-1 system
alters 5-HT levels, and that the direction of this modulation depends on the site of action,
animal model, and type of exposure.

122

A study in 2016 looked at the effects of acute and chronic (9 days) Ex-4 on emotionality
and its relationship to 5-HT (Anderberg et al, 2016). In this study, acute central
administration (LV) of Ex-4 increased anxiety-like behavior—in the light/dark box and
open field test—and increased 5-HT turnover and receptor expression in the amygdala.
Surprisingly, the changes in 5-HT turnover and receptor expression were not observed
in the animals that received chronic treatment with Ex-4. Despite the lack of changes to
5-HT in the amygdala, this group of animals showed decreased depressive-like behavior
in the forced swim test (Anderberg et al, 2016). This goes to highlight that while this and
other studies have found that chronic treatment with GLP-1R agonists decrease
depressive-like behavior (Isacson et al, 2011; Komsuoglu Celikyurt et al, 2014; Sharma
et al, 2015) its effect on the 5-HT system remains elusive.

The lack of literature and complexity of interactions make it difficult to predict how
chronic treatment with GLP-1-based therapies will impact the 5-HT system and its
interaction with the HPA axis. Pre-clinical and clinical studies are required to address the
multiple facets this question presents. In the simplest scenario, the effects of chronic
treatment with GLP-1R agonists on systemic and central 5-HT levels should be
assessed in pre-clinical models. This effect is likely to be influence by the presence or
absence of stress, as such, stress should be a variable that is considered in the
experimental design. What further complicates this question is that individuals who are
on GLP-1-based drugs are likely already in a pathological state and may have
dysregulated stress mechanisms and altered stress response. The magnitude and
directionality of these changes are hard to predict and harder to model. A way to get
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around this would be to compare the effects of chronic treatment with GLP-1Rs agonists
on mood and 5-HT levels in individuals with and without a stress-related comorbidity. To
account for pathological changes associated to metabolic disease, patients would have
to be of similar medical background (either obese, diabetic, or both).

Despite the clear and ever-growing evidence that GLP-1 and 5-HT interact, there is no
evidence of a serotonergic syndrome response to GLP-1 based pharmacotherapies.
This supports the possibility of developing combo treatments to treat not only metabolic
diseases, but also neuropsychiatric disorders. At the same time, there is no data to rule
out the possibility that chronic treatment with GLP-1-based pharmacotherapies could
disturb the effects of antidepressants whose mechanism of action relies on modifications
to the 5-HT system. Moving forward, a more detailed characterization of behavioral and
physiological effects will determine the possibility of the development of substitute or
combo therapy for metabolic and other disorders.

Effect of obesity and diabetes on GLP-1’s responsivity to stress
The effect metabolic disease has on the ability of GLP-1 to influence stress centers has
not been directly studied. Nonetheless, there is literature that examines the effects of
metabolic disease on GLP-1 and, separately, on the HPA axis. This section will overlap
that literature with GLP-1’s role in modulating the stress response in order to explore the
potential modifications that chronic perturbations to the GLP-1 system—that result from
metabolic disease—can have on GLP-1’s responsivity to stress.
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Effects of obesity and diabetes on the GLP-1 system. Obesity is associated with reduced
GLP-1 signaling in the periphery as well as the CNS (Anandhakrishnan and Korbonits,
2016). In fact, studies show that meal-induced increases in GLP-1 are reduced with
increasing body mass index (BMI) (Færch et al, 2015; Muscelli et al, 2008; Nauck and
Meier, 2018; Ranganath et al, 1996). However, the mechanisms that underlie the
reduced incretin effects of GLP-1 in obese patients and when in the course of the
development of obesity those changes occur are unclear (Nauck et al, 2018). The effect
of type 2 diabetes on post-prandial GLP-1 release is still contested. Some studies report
type 2 diabetic patients having a reduced GLP-1 response following a mixed meal when
compared to healthy matched subjects (Toft-Nielsen et al, 2001; Vilsbøll et al, 2001),
while other studies found no difference (Theodorakis et al, 2006; Vollmer et al, 2008).
Metanalyses indicate that there is no difference in nutrient-induced secretion of GLP-1
between type 2 diabetic patients and their control counterparts (Calanna et al, 2013;
Nauck et al, 2011). In fact, it’s been suggested that impairments in GLP-1 secretion
might be a “consequence rather than a cause” of type 2 diabetes mellitus (Meier and
Nauck, 2008). While levels of secreted GLP-1 seem to be mostly unaffected, what is
affected in type 2 diabetes is GLP-1’s insulinotropic effect. A study in 2003 revealed that
while GLP-1 did elicit an insulinotropic effect in diabetic patients the magnitude of this
effect was significantly reduced when compared to healthy subjects (Kjems et al, 2003).
This effect is thought to be due to reduced number of β-cells and defects in the β-cells
function. This is supported by studies showing reduced β-cell mass and defects in insulin
secretion in type 2 diabetes (Byrne et al, 1996; Klöppel et al, 1985; Ward et al, 1984).
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Effects of obesity and diabetes on the HPA axis and the stress response. Diabetes
causes chronic activation of the HPA axis and may, in the long-term, contribute to insulin
resistance (Diz-Chaves et al, 2016). The effect type 2 diabetes mellitus has on HPA
dysregulation is reflected in elevated basal ACTH and cortisol levels (Chiodini et al,
2006; Prpić-Križevac et al, 2012). A metanalysis looking at HPA axis dysregulation and
cortisol activity in obesity concluded that increased abdominal obesity has a positive
correlation with hyperactivity of the HPA axis (Incollingo Rodriguez et al, 2015). There
are various aspects of HPA activity that are dysregulated in obese individuals. Three
separate studies have found a positive correlation between generalized obesity and
cortisol awakening response (CAR), which refers to the spike in cortisol concentrations
that occurs just after waking up (Steptoe et al, 2004; Therrien et al, 2007; Wallerius et al,
2003). Irregularities in CAR is considered the greatest indication of HPA axis
dysregulation (Incollingo Rodriguez et al, 2015). Another measure of HPA activity that is
abnormal in obese patients is the diurnal cortisol response, which measures daily
pattern of cortisol concentrations. A normal response comprises a negative slope, where
cortisol increases sharply shortly after waking (i.e. CAR) and declines throughout the
day. Flat tops—responses that lack a pronounced CAR or do not reflect a significant
cortisol reduction throughout the day—are indicative of HPA dysregulation. Champaneri
et al., found that higher BMI and waist-to-hip ratios (WHR) are associated with diurnal
cortisol responses with flatter and less pronounced declining slopes (Champaneri et al,
2013). Additional studies have also found increased total daily output (cumulative
measure of cortisol concentrations throughout the day) and increased cortisol reactivity
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(spike in cortisol concentrations observed after either physical or psychological
stressors) in obese patients (Mårin et al, 1992; Purnell et al, 2004; Rask et al, 2002;
Rosmond et al, 1998; Stewart et al, 1999). It is worth noting that there are some
inconsistencies in the literature regarding the relationship between obesity and the
aforementioned indices of HPA activity; the strongest and most consistent predictor
seems to cortisol reactivity (Incollingo Rodriguez et al, 2015).

Adipocyte

cortisol

metabolism—

which

functions

through

11-beta-hydrosteroid

dehydrogenase 1 (11β-HSD1)—also plays a role in the HPA dysregulation observed in
obesity and potentially diabetes. 11β-HSD1 is an enzyme that catalyzes the intracellular
regeneration of cortisol from inactive cortisone (Chapman et al, 2013) and amplifies the
effects of cortisol in the liver and fat cells (Seckl, 2004). Increased body weight
correlates with increased 11β-HSD1 expression in fat cells; this pattern has been
reported by multiple studies in both rodents and humans [for review see (Incollingo
Rodriguez et al, 2015)]. In humans, increased 11β-HSD1 is observed in obese males
and females and one study even reported a two-fold difference between obese and nonobese females (Engeli et al, 2004). It’s been suggested that increased 11β-HSD1 in
obese patients leads to higher intra-adipose cortisol levels and may promote the
accumulation of visceral adipose tissue (Diz-Chaves et al, 2016). A recent report
suggests that increased 11β-HSD1 is also observed in patients with type 2 diabetes
(Shukla et al, 2019), though the role it plays in diabetes-associated pathology is still
being determined.
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Collectively, patients with either diabetes or obesity have a hyperactive HPA axis under
basal conditions. What is not yet clear is the chronological order of events, whether HPA
axis dysfunction is a precursor of metabolic disease or if physiological changes caused
by diabetes/obesity result in altered regulation of the HPA axis.

Potential effect of chronically dampened GLP-1 signaling on stress responsivity. As
discussed above, empirical evidence supports the presence of hyperreactive HPA in
patients with obesity and diabetes, which results in increased basal activity (i.e. ACTH
and cortisol levels) and increased hormonal response to stressors. Meanwhile, obesity
and diabetes hamper the GLP-1 system causing either decreased GLP-1 levels or
reduced efficacy of GLP-1 functions. Kamei et al. showed that a 12-week treatment with
Liraglutide (0.9mg/kg) significantly reduced ACTH and cortisol levels in patients with
type 2 diabetes (Kamei et al, 2017), suggesting that the hyperactive HPA activity present
in diabetic patients might be linked to alterations in the GLP-1 system. There is evidence
to suggest that GLP-1’s role in normalizing HPA activity is engaged only in the presence
of pathology. Support for this comes from a 2017 study in which a 3-week treatment with
liraglutide caused no changes in ACTH or cortisol in healthy individuals (Sedman et al,
2017). In the absence of disease, acute administration of GLP-1 increases
ACTH/corticosterone levels, yet chronic activation of GLP-1Rs in diabetic patients
decreases ACTH/cortisol. Although, it is unclear if these changes are driven by the
continuous engagement of the GLP-1 system or if they come about as a consequence of
the pathological state of the system. It’s possible that metabolic disease inverts GLP-1’s
effect on HPA axis activity. Additional studies are required to confirm if that’s the case as
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well as to identify the mechanism underlying the changes in GLP-1 in the presence of
metabolic disease.

Conclusion
The tightly intertwined relationship between the 5-HT and GLP-1 systems is starting to
become uncovered. Thus far, this relationship seems to be bidirectional, involve multiple
receptors across many organs, and influences many physiological and behavioral
outputs. The data presented in this dissertation contributes to the scientific literature by
examining the relationship between these systems within the hindbrain and elucidating
how that interaction affects feeding and stress-induced neuronal activation. Collectively,
this body of work emphasizes the complexity of neurotransmitter / -peptide systems and
the importance of how they interact. The collective body of work presented here shows
that 5-HT is a modulator of the central GLP-1 system and identifies a potential direct
mechanism in which 5-HT engages NTS PPG neurons by activating 5-HT2C/5-HT3
receptors. Further, these data highlight the RMg as a novel target for future research
involving serotonergic modulation of the central GLP-1 system. Finally, it confirmed that
the 5-HT/GLP-1 interaction within the brain is behaviorally relevant (Fig 4.2).
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Figures

Figure 4.1. Table summary of scientific articles on the interaction between 5-HT and GLP-1.
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Figure 4.2. Dissertation’s contribution to the field.
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